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SUMMAR ~ 
Conditions for the viable ma intenance of the isolated rat hypothalamus 
in culture , have been investigated. Hank's and Earle's media were 
suitable for inc~bation but tissue necrosis occurred rapidly in 
Eagl e 's Minimal Essential medium. Hypothalami were suspended in Hank\s 
physiological buffer and factors affecting the release of luteinizing 
hormone releasing hormone (LHRH) and immunoreactive somatostatin (IRS), 
investigated. The viability of the tissue was assessed by oxygen 
consumption and by th~ rate of protein synthesis. 'Protein synth,esis 
continued for up to 60 min but declined rapidly during the next 60 min 
of incubation. Amino acid uptake, however, remained active for 90 ~in. 
The rate of LHRH release was constant for the first 60 min of incubation 
(140 pg/h), thereafter increasing to very h.igh levels (250 pg/h,) conc6mitant 
with the decline in protein synthesis, suggestive of loss of cellular 
integrity and peptide leakage. Rel.ease of· Ll\RH from the incubated 
hypothalamus was found to be a temperature dependent process. 
LHRH. degrading peptidases were sec~eted by the hypothalamus. The peptidase 
inhibitor, bacitracin (1,0-3M), completely inhibited LHRH: degrad~tion and 
was thus included in the incubation, -µie~_ium. in a.11 studies. 
· In viabl,e hypotha'l,ami.,.reiease of LHRH an.cl, IRS was less than 5% o;f th,e total 
tissue content. There was no ·nett £Ilcrease in tissue content of LHRH 
or IR,S during incubation .. 
. 2+ + 
In the presen'-C..ot l .tru'1 Ca , 60 mM K stimulc\ted both LHRH and I.RS ,release, 
Th . 1 . p 1 • h 2+ ( 2+ ere was no stur.u ation, 0.1, rei.ec1se int e absence of Ca Ca, free medium 
2+ 
+ 0.5 mM EGTA) or in the presence of veraparmil (20p) 1 a. Ca chc1nnel blocker. 
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The ionophore X537A (lµM) increased the release of LHRH and IRS. 
Veraparnil completely inhibited XS37A induced release of LHRH. but only 
partially inhibited the release of IRS. The ionopho~~ A23187 (lpM) 
increased IRS release but decreased LHRH release. Verapamil did not 
affect the ionophore - induced response of the two neuropeptides. 
These findings point to differences :inthe mode of action of the two 
ionophores and suggest a difference in the mechanism of release of 
LHRH and IRS from the incubated hypothalamus. 
Although extensive data are available on the effect of neurotransmitters 
on the secretion of anterior pituitary hormones in vivo little is known 
about the physiological and biochemical mechanism of their action in 
this regard. Many neurotransmitter effects may be mediated yia their 
influences on the secretory activity of the hypothalamic peptidergic 
neurons. In the present study it was found that certain biogenic 
amines (10-SM to l0-7M) influence the release of LHRH and IRS and that 
these effects differ for the two peptides. LHRH release was decreased. 
by GABA and increased by melatonin, serotonin, noradrenalin, and adrenalin. 
L-DOPA, dopamine, acetylcholine and histamine were withou:t effect on 
LHRH release from rat hypothalami, IRS release was decreased by 
histamine and increased by serotoAin, me'l,a.tonin and adrenal.in.. ;Noradrenalin, 
L-Dopa, dopamine, ac~tylcholine and GABA. were without effect on IRS release 
from the incubated hypothalamus. 
The effect of a number of neuropeptides (50 - 500 ng}ml) on LB.RH and' IR,S 
release from the incubated rat hypotha'Lami were inyestigated, Th~ basal 
release of LHR.H was decreased when hy{>otha.lami were incubated in. the 
presence of oxytocin and vasopressin, TRH, somatostatin-t4, neurotensin, 
substance P, met-€nkephalin and leu-enkephalin did not a'l,ter the basal, 
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release of LHRH. The effect of ~-endorphin could not be determined 
since the peptide was found to interfere with the LHRH radioinununoassay. 
The basal release of IRS was increased by neurotensin, substance P, LHRH 
and TRH. Met-enkephalin, leu-enkephalin, vasopressin, oxytocin and 
~-endorphin did not alter the basal release of IRS from the incubated 
hypothalami. 
The feedback regulation of LHRH release by anterior pituitary gonadotrophic 
hormones and gonadal hormones may in part be mediated by alteration in 
LHRH secretion. 
LHRH release was unaffected by in vitro addition to testosterone 
proprionate (20 - 50 ng/ml), ~-oestradiol (20 - 50 pg/ml), LR 
(luteinizing hormone) (1 - 100 ng/ml) and the LHRH agonist des - 9ly 10-
D-leu6 - LHRH ethylamide (10 - 50 ng/ml). IRS release was markedly 
increased by the in vitro addition of p-oestradiol (20 - 50 pg/ml). 
When rats were castrated LHRH release from their isolated hypothalami 
was significantly less than that from hypothalami isolated from intact 
rats. This release was unaltered by in vivo pretreatment of castrated 
rats with testosterone proprionate (100 µg/day) or p-oestradiol (lpg/day). 
There was an increase in hypothalamic LHRH release when intact rats 
were pretreated in~ with p-oestradiol (lµg/day). IRS release from 
hypothalami of castrated rats was increased by in vivo pretreatment 
with p-oestradiol. 
Our investigations have established that functionally active, excised 
hypothalami can be maintained in vitro for 60 min as indicated by 
oxygen consumption, protein synthesis and the ability to stimulate 
neuropeptide release. This sytem has been shown to be suitable for 
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investigating the biochemistry of neurosecretion, the role of 
neurotransmitters and neuropeptides in neurosecretion and the mode 
of action of hormones 1.n feedback regulation of hypothalamic LHRH 
and IRS release. 
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1. INTRODUCTION 
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I N T R O D U C T I O N 
In 1849, Berthold demonstrated that if testes were transplanted 
into castrated cocks, normal male development was maintained in the 
birds. This was the first paper of any importance in the field of 
endocrinology as it established that if a particular organ is an 
endocrine gland it will maintain its normal function if transplanted 
at a distant site in the body (Harris,1955). However,it was not until 
the 1930's that physiological evidence for the regulation by the CNS of 
gonadotrophin secretion from the pituitary was postulated. In 1928 
working on the diencephalon of teleost fish Ernest Scharrer proposed 
the classical neurosecretct.ry cell which possessed both neuronal and 
endocrine properties. This neurosecretory concept was further extended 
by the discovery of a hypothalamic - hypophyseal portal vascular system 
in mannnals (Popa and Fielding, 1930 ; Wislocki and King, 1936). 
Initially, the hypothalamus was thought to activate the posterior lobe 
of the pituitary which in turn activated the anterior lobe of the 
pituitary by humoral transmission (Hinsey and Markee, 1933). Direct 
humoral impulses to the adenohypophysis were proposed by Friedgood 
(1936), Harris (1937) and Brooks (1938). Taubenhaus and Saskin (1941) 
suggested from their work on the rat hypophysial portal vessels that 
an acetylcholine-like substance was carried from the hypothalamus 
to the anterior pituitary. A more detailed study on humoral trans-
mission by Harris (1944) and Green and Harris (1947) established that 
in mannnals there was no major tract of nerve fibres connecting 
the hypothalamus and anterior pituitary. They proposed that pituitary 
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function was controlled by humoral substances which were 
secreted by the hypothalamus into the portal system. These early ideas of 
ne~rohumoral regulation of the function of; the anterior J?ituitary 
gland were based on experiments involving electrical stimulation or 
lesioning of the hypothalamus, transplantation of the gland or 
sectioning of the pituitary stalk and thus interrupting the blood 
supply between the hypothalamus and the pituitary. Studies on the 
functional activity of the target organ of the anterior pituitary 
hormones (ovary, testis, adrenal cortex and thyroid) after the 
treatments revealed that regulation of pituitary hormone secretion 
was dependent on the integrity of its hypophysial portal blood supply. 
It was concluded that these portal vessels which arise in the median 
eminence as capillaries of the primary plexus, carry humoral agents 
(the releasing and inhibiting factors) from the hypothalamuD to the 
pituitary. The blood borne releasing factors translate neural 
impulses in the CNS into biochemical responses by increasing or 
decreasing the secretion of the appropriate trophic hormone from the 
anterior pituitary. 
Initially, the blood flow in the portal system was thought to be from 
the pituitary to the hypothalamus (Popa and Fielding, 1930; Wislocki 
and King, 1936). However, Green and Harris (1949) established that 
the blood flow in the portal vesse1s was from the tuber cinereum to the 
"' adenohypophysis. It was on the basis of these conclusions that studies 
were initiated to isolate the releasing and inhibiting factors from 
the hypothalamus and it led to their successful isolation,characterisation 
and synthesis by Sch.ally and Guillemin. It is therefore significant 
that Oliver et al (1977) and more recently,Bergland and Page (1979) 
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have provided evidence that there is retrograde blood flow away from 
the pituitary towards the hypothalamus and other brain areas. This 
offers potential for short loop feed-back regulation and the possibility 
that the hypothalamus can metabolize pituitary peptides e.g. ~-lipotrophin 
to ~-endorphin (Fig. la~. 
A large number of physiological studies established that the majority 
of physiological processes are ultimately regulated by release and 
release-inhibiting factors secreted by the hypothalamus. These factors 
were found to control the pituitary hormones involved in regulating 
reproduction (FSH and LH), growth (GR), ~arbohydrate metabolism (ACTH), 
thryoid function (TSH), milk production (PRL), pigmentation (MSR), 
water balance (ADH or vasopressin) and uterine contraction (oxytocin) 
(Blackwell and Guillemin, 1973; Schally et al, 1973; Petersen and Guillemin, 
1974). 
The hypothalamus is an area of: the diencephalon lying at the base of the 
brain, ventral to the thalamus and forming the floor and part of 
the lateral walls of the third ventricle. It is bounded anteriorly 
by the optic chiasma and posteriorly by the mamillary bodies (Fig. lb). 
-The median eminence of the tuber cinereum, in the floor of the third 
ventricle, is connected to the pituitary by means of a stalk (Schally 
et al, 1973). 
The first of these hypothalamic hypophysiotrophic factors (Table 1.1) 
to be isolated was a tripeptide>thyrotrophin - releasing factor 
(TRF, TRH) by Burgus et al (1969, 1970), who purified 300,000 sheep 
hypothalami to isolate 1 mg TRH. Concurrentl~ Schally's group 
- 16 -
FIGURE l.l(a) Diagram of the vasculature of the rhesus monkey pituitary; 
posterior view. The posterior portion of the infundibulum has been removed 
and the arrows indicate the potential routes from the neurohypophysis since 
adenohypophyseal secretions are conveyed to the capillary bed of the neuro-
hypophysis where they may leave via any of 7 potential routes. 1) portal 
vessels to adenohypophysis 2) to cavernous sinus 3) infundibulum to hypothalamus 
4) tanycyte transport into the ventricles 5) leakage through fenestrations 
of the portal vessels 6) arteriesmay serve as efferent vascular channels 
7) retrograde axonal flow to the hypothalamus. Five of these routes are 
directed to the brain (from Bergland and Page, 1978). 
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reported the structure of porcine TRH to be identical to that of ovine 
TRH (Nair et al, 1970). 
In 1971 Schally's group characterized the structure of the decapeptide 
luteinizing hormone - releasing hormone (LHRH) which stimulated the 
release of both LH and FSH from pituitary cells in culture. Later that 
year Guillemin's group confirmed the structure from material of ovine 
origin (Burgus et al, 1972). Two years later, Guillemin's group 
(Vale et al, 1972) characterized a cyclic tetradecapeptide somatostatin 
(SS) which possessed potent GH release-inhibiting properties. Schally's 
group found the structure of porcine somatostatin to be identical (Coy 
et al, 1973). A number of higher molecular weight innnunoreactive species 
of somatostatin have since been described in various tissues and shown 
to have biological activity. (Schally et al, 1975; Zingg and Patel, 1979; 
Vale et al, 1976; Millar, 1978; Spiess and Vale, 1978, 1980; Rorstad et 
al, 1979). Recently, a twenty eight amino acid form of somatostatin was 
isolated from porcine intestine by PradayrQl et al (1980) and was 
subsequently isolated in extracts of ovine hypothalami (Brazeau et al, 1980) 
and porcine hypothalami (Schally et al, 1980). It has been shown to have 
GH inhibiting activity equal to or fourteen times greater than that 
of the tetradecapeptide somatostatin. Other proposed putative 
hypothalamic factors which have not as yet been isolated are CRF (ACTH), 
PIF and PRF (PRL), MIF and MRF (MSH) and GRF (GH). Morphine is 
known to release GH, thus it seemed possible that an endogenous opiate like 
substance may be involved in the release of GH as well as other pituitary 
hormones. Hughes et al (1975) isolated the opioid pentapeptides leu- and 
met-enkephalin from brain extracts and in 1976, Li et a1, isolated the 
untriakontapeptide,~endorphin1 from the camel pituitary gland. 
- 20 -
Subsequently, the enkephalins were localized to neurons and cell bodies 
within the hypothalamus (Hokfelt et al, 1977). Of the endogenous opiate 
peptides isolated to dat~only these three have any claim to a 
physiological function (Beaumont and Hughes, 1979). It is clear that 
there is a very close and complex relationship between opioid peptide s 
and hypothalamic mechanisms which may explain some of their effects o~ 
GR, PRL, LH, FSH, and ADH secretion from the pituitary gland. However, 
enkephalins do not appear to be releasing and inhibiting factors 
because they do not have a direct effect on pituitary hormones. They 
probably operate in a similar way to neurotransmitters in stimulating 
or inhibiting peptidergic neurons which secrete releasing and inhibiting 
factors. 
Once LHRH, somatostatin and TRH had been synthesized it was possible to 
render these peptides immunogenic by linkage to hapten carriers. Thus 
specific antibodies were produced and used in radioimmunoassays (RIA) which 
allowed for quantitation and localization of the peptides in tissues and 
biological fluids. 
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DISTR!BUTION AND BIOLOGICAL ACTION OF LHRH. 
DISTRIBUTION 
Studies based on the direct determination of LHRH by RIA of extracts 
from either thin hypothalamic slices (Wheaton et al,1975) or discrete 
hypothalamic nuclei, removed by "punch techniques" (Palkov.its et al, 197!1)., 
showed a similar distribution pattern for the neuropeptide. LHRR 
is found over the optic chiasma;and in the region extending caudally 
along the base of the brain to the ME (Fig. l? ) . The bulk of LHRH is 
concentrated in the ME and arcuate nucleus region (85% of total 
hypothalamic content). These findings are in good agreement with 
earlier work (Mccann, 1962; Crighton et al, 1970; Quijada et al, 1971). 
A large part of the preoptic LHRH is concentrated extrahypothalamically 
in the OVLT (Wheaton et al, 1975). It was first detected in this 
region by immunohistological techniques (Zimmerman et al,1974) and 
later confirmed by RIA of extracts of OVLT (Kizer et al,1976). 
Smaller, but significant quantities of LHRH have been found in the 
remaining periventricular organs (subfornical, subcomisural and 
area postrema),the amygdala, the para-olfactorycortex (Hokfelt et 
al ,1976), and in the pineal gland (Kizer et al,1976; Jonas et al, 1975~ 
White et al, 1974 ·; Gross, 1976) . 
• 
BIOLOGICAL ACTION 
LHRH is kno'il.'11 to stimulate the release of LR and FSH, induce 
ovulation and increase sperm counts and the production of gonadal 
steroids in a variety of species (Vale et al,1977). Immunisation of 
experimental animals against LHRH results in a decrease in serum 
LH and FSH levels, infertility, and gonadal atrophy (Arimura et al, 
1973,1974). To date no substance has been isolated which selectively 
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modulates FSH secre tion, although clinical and experimental 
circumstances do exist in which secretion of LR and FSH can be 
dissocia ted. A possible explana tion is that LHRH is the only 
hypo t halamic stimulator of LH and FSH release but per ipheral, and 1.n 
particular gonadal factors, may have differential feedback effects 
on the rel ease of individual hormones from the ant erior pituitary. 
Inhibin, an aqueous testicular and ovarian extract has been reported 
to s e lectively block the spontaneous and LHRH-induced s ecretion of 
FSH but not LR (Franchimont et al, 1975; Setchell and Jacks, 1974). 
The effect of inhibin is probably exerted synergistically with these 
of the gonadal steroids (Labrie et al,1979). Androgens have also 
been shown to have not only specific but also opposite effects at 
the pituitary level on the control of LR and FSH secretion, while 
estrogens stimulate LR and FSH secretion and progesterone stimulates 
FSH but ha s a biphasic effect on LH secretion. (Drouin and Labrie, 1976; 
Labrie et al , 1979; (Fig. 1. 2 ) 
The existence of LHRH in extrahypothalamic nerve fibres, taken together 
' with behavioural studies support a possible direct action of LHRH on the 
CNS that could modulate sexual behaviour independently of the gonadal 
steroids or the pituitary gonadotropin status of the animal. Thus 
delivery of LHRH to appropriate neural cells mediating this response 
could occur either by direct projections of the LHRH neurons or 
by transport through the CSF (Vale et al, 1977). 
Immunocytochemical evidence suggests that LR and FSH are contained 
within the same pituitary cell type (Herbert, 1976). A prerequisite 
for secretion of the pituitary hormones appears to involve the binding 
of LHRH to a specific receptor on the plasma membrane of the 
FIGURE l. 2 
- 23 -
CNS 
__ -+ LH FSH + 
OESTROGENS 
ANDROGENS 
PROGESTINS 
INHIBIN 
Schematic representation of the feedback regulation 
of LHRH secretion. 
(modified from Labrie et al, 1979) 
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pituitary cell. Studies with analogues have established that nearly 
the complete decapeptide sequence of LHRH is required for biological 
activity. This implies that strict structural features are implicit 
to the receptor binding LHRH. The mechanism of action of the 
neuropeptide at the level of the pituitary cell is unknown although 
d . 'b . f 2+ . h d . 11 ( k' d 1 a re 1.str1 ution o Ca" 1.n t e gona otrop1.n ce Hop 1.ns an Wa ker, . 
1978) and the adenyl cyclase system (Labrie et al, 1979) have been 
implicated. 
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DISTRIBUTION AND BIOLOGICAL ACTION OF SOMATOSTATIN 
DISTRIBUTION 
Growth hormone release-inhibiting activitiy was first detected by 
Krulich et al , (1971) . in the ME and to a lesser extent in the 
suprachiasmatic area of rat brain. Subsequently somatostatin was 
found in many other sites in the CNS. Other areas of the hypothalamus 
with high concentration of somatostatin are the arcuate, ventromedial, 
ventral premaxillary and the periventricular nuclei. Somatostatin is 
found in much lower concentrations in the periventricular organs and 
· pineal gland (Brownstein et al, 1975; Kizer et al, 1976). The 
distrubition of somatostatin is not limited to the CNS structure as 
large amounts are found in the gastrointestinal tract, the pancreas and 
the thyroid gland (Hokfelt et al, 1975; Arimura et al, 1975(a); Leclerc et 
al, 1976; Parsons et al, 1976). 
BIOLOGICAL ACTION 
Somatostatin inhibits GR release in~ and in vitro in response to 
virtually every known stimulus in man and animals. It also inhibits 
the release of TSH, ACTH, insulin, glucagon, pancreatic polypeptide, 
gastrin, cholecystokinin,pancreozymin, secretin, VIP, renin, PTH 
and calcitonin to name some of its endocrine actions. Somatostatin 
has also been shown to inhibit or decrease non-endocrine phenomena 
such as platelet aggregation and acetylcholine release in addition 
to effects on the CNS. (Sheppard, 1979, a comprehensive review). 
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Somatostatin does not inhibit indiscrimantly as it has been 
shown to be without effect on LH and FSH secretion, and the release 
_of steroids from the adrenal cortex and the gonads in normal animals 
(Vale et al, 1977). 
Sincesomatostatin has a short biological half life in the peripheral 
circulation it is unlikely that any effect of the neuropeptide on the 
endocrine pancreas is due to somatostatin of hypothalamic origin. 
The D cells of ·the pancreas have been shown to have long cytoplasmic 
processes terminating on other cell types where local release of 
somatostatin could control their function. This suggestsparacrine 
regulation by somatostatin of glucagon, insulin and gastrin 
secretion from the pancreas (Larsson et al, 1979). 
The mechanism by which somatostatin exerts the inhibitory _action 
. d d ' h 2 + 
- is not un erstoo . Interference wit Ca transport at the nerve 
terminals and in the pancreas as well as an inhibitory effect on 
' ' 1· d 2 + ' ' pituitary eye ic AMP an Ca accumulation have been described 
(Tan et al, 1977; Curry and Benett, 1976; Ishibashi et al, 1979; 
Borgeot et al, 1974; Bicknell and Schofield, 1976). 
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DEGRADATION OF LHRH AND SOMATOSTATIN 
Degradative enzymes may play a part in controlling hormone action by: 
(i) regulating the amount of hormone available for release at 
the site of production 
(ii) regul a ting the amount of hormone actually reaching site of action 
(iii) controlling the duration of action through hormonal inactivation 
at the receptor sites in a particular target tissue. 
(iv) the r emoval of the hormone from the general circulation so that too 
large a response to the hormone is pre~ented. 
Proteolytic enzymes are responsible for the inactivation of the active 
peptide into inactive metabolites which may be rapidly excreted 
or recirculated and reutilised by the body (Marks, 1977; Griffiths and 
Kelly, 1979). 
DEGRADATION OF LHRH 
Inactivation of LHRH by hypothalamic extracts were first reported by 
Griffiths et al . (1973) · and Sandow et al (1973). The peptidase activity 
' 
inactivating LHRH changes with castration and gonadal steroid injection 
(Griffiths et al, 1975),with neonatal androgen treatment (Griffiths et al, 1976), 
at a time of puberty (Griffiths et al, 1978) and under the infiuence of 
dopamine (Marcano de Cotte et al, 1980). This suggests that the enzymes may 
have a functional significance in controlling the amount of LHRH available 
for release from the hypothalamus. It has also been suggested 
that the peptidases in the hypothalamus may be responsible for activation of 
- 28 -
LHRH from the parent pre prohormone (Millar et a.1, iJ..97.S(b)) .. 
The hypothalamic peptidases inactivating LHRH are knovm to interfere 
with in vitro studies of LHRH biosynthesis and release (McKelvy et al, 
1976). Thus the polypeptide antibiotic, bacitracin was used to inhibit 
degradation of LHRH released. Bacitracin completely inhibits the 
-4 -5 peptidases at a concentration of 10 Mand has a Ki of 1.9 x 10 M 
(See Chapter 2). 
Subcellularly, the enzymes are present in soluble/cytoplasmic and 
particulate fractionsand have an optimum pH of 7.4. Part of the 
specificity is naturally inferred on LHRH by nature of its bl.ocked C and 
N terminal ends. For the degradation of LHRH, Loudes et al : (1978), 
have determined that the peptidase has a Km of 2.t x 10-8M, although 
Sundberg and Knigge (1978), have calculated a Km of 2.1 x l0-8~ 
and V max of 1.7 pg/min/pg protein. 
Several sites of enzymic cle~vage of the decapeptide have been indicated. 
Marks (1977) has suggested that cleavage of the Gly-NH 10 trom the C 2. 
terminus may occur. Subsequently a pyroglutamate aminopeptidase (Bauer 
et al, 1979) and a post-praline cleaving enzyme (Knisatschek and Bauer, 
1979; Hersch ~nd McKelvy, 1979) have beenisolated from brain and pituita 
t 2 9 10 extracts, which cleave the pyro-Glu ·-His bond and the Pro -Gly-NH2 bond. 
A more controversial issue is the reported cleavage of the Tyr5-G1y6 bond 
(Hudson et al, 1976) and/or the Gly6-leu7 bond (Koch et al, 19,74; 
Fridkin et al, 1977; Akapyon et al, 1979) by brain, hypothalamus, 
pituitary and liver extracts. Koch et al (1974) and Kelly et al (1978) 
have found that the 1-6 sequence of LHRH is the on'.ly product of 
enzyme cleavage detectable using extracts from hypothalamic and 
- 29 -
pituitary tissue. More recently a non-chymotrypsin- like endopeptidase 
has been partially purified and characterized from anterior pituitary 
5 6 . 2 3 
extracts, which cleaves LHRH (Km=l80pM) at the Tyr -Gly and His -Trp 
bonds (Horsthemke and Bauer, 1980) (Fig. 1.3). Thus it is apparent 
that there must be several LHRH degrading enzymes and also amino ,and 
, I 
carboxy peptidases in tissue extracts which may subject the initial 
cleavage products to further degradation. 
DEGRADATION OF SOMATOSTATIN 
Enzymes degrading somatostatin-14 have been extracted from the thalamus, 
cerebellum1cortex and hypothalamus. Little is knovm about the subcellular 
distribution of these peptidases. It has shown that soluble and 
particulate subcellular fractions prepared from the hypothalamus 
rapidly degrade soma 'tostatin. The peptidases involved have an optimum 
pH at 7.4 and a second peak at pH 9.0 and are specific for somastostatin 
(Griffiths et al, 1977; Dupont et al, 1978). Some specificity is probably 
due to the cyclic nature of somastostatin and in agreement with the 
studies of Marks (1976), the hypothalamic neutral peptidases appear 
to cleave the Trp-Lys bond initially although other sites of action 
are possible (Kelly et al, 1978). A non-specific neutral peptidase (pH 7.0) 
purified from bovine hypothalamic extracts (Akopyan et al, 1978) is thought 
4 5 6 6 7 1'0 1'1' to cleave at the Asp -Phe , Phe .,..Phe or The -Phe , · bonds. An c1;cid 
peptidase (pH 3.2) isolated from hypothalamic extracts may also be 
involved (Akopyan et al, 1978). 
Recently, a neutral peptidase in hypothaiamic extracts h,as been shown to 
convert a high molecular weight inununoreactive species (25K) of 
I:,, 
som~statin to an intermediate immunoreactive species (4K) and somatostatin-
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14 (Zingg and Patel, 1980). Thus it appears that peptidases are 
important in the cleavage and activation of prohormones and thus may have 
a regulatory role in controlling somatostatin levels in the hypothalamus 
(Fig.1.3). 
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NEUROSECRETORY MECHANISMS 
In the last decade it has become apparent that many of the polypeptide 
hormones are . synthesized by way of a prohormone. The prohormone may 
C 
be derived from precursor molecule, the preprohormone,which has an 
additional sequence of hydrophobic residues at the amino terminus. 
Blobel and Dobberstein (1975) predicted such prepeptides in the 
biosynthetic pathway for secretory polypeptides as part of the "signal 
hypothesis" to explain translocation of newly synthesized polypeptides 
into the lumen of the endoplasmic reticulum. 
Supportive evidence for the existence of a precursor of LHRH was the 
isolation of a putative high molecular weight inmmnoreactive form of 
LHRH (Millar et al, 1977, 1978). Although little is known of the 
biosynthesis of somatostatin a number of high molecular weight 
innnunoreactive species (25K-5K) have been described, Spiess and Vale 
(1980) isolated 12K, 4K and 2K innnunoreactive species of somatostatin and 
proposed that the larger innnunoreactive species are prosomatostatin fragments 
possibly intermediates in the precursor product conversion, Similarly 
Pradayrol et al (1980) and Schal,ly et d (1980) proposed that somatostatin-
28 may be a prohormonal form of somatostatin-14. However, Guillemin's 
group (Brazeau et al, 1980) proposed that somatostatin-14, as originally 
isolated, may be a biologically active fragment of a larger molecule 
of greater specific activity. In view of their biological activity 
and the fact that the 3K and somatostatin-14 species are contained 
in and isolated from SME synaptosomes (Kewley, 1981) it is conceivable 
that they are both products of a larger prohormonal form. 
Most of the work on peptide neurosecretion has been done on the 
release of oxytocin, vasopressin and the neurophysins from the posterior 
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pituitary (Gainer et al, 1979). This system may be regarded as a 
classical mode l for neurosecretion and may be analogous to the 
biosynthesis and secretion of LHRH and somatostatin from the hypothalamus 
into the hypophyseal portal system. Thus it hypothesized that a high 
molecular weight precursor form of the neuropeptide is synthesized 
ribosomally in the cell bodies (Millar et al, 1978). Once synthesized 
the high molecular weight precursor is sequestered into vesicles in the 
Golgi and transported along the axon to the nerve terminal where 
the vesicles are stored prior to secretion. The vesicles may contain 
the enzymes necessary for the post-translationa~ processing of the 
prohormones to smaller peptide products, although to date none have 
been isolated. 
Some. neuropeptides, including LHRH, and many neurotransmitters have 
been shown to be localised in two storage pools, viz .. a small "readily 
releasable pool" and a larger storage pool whose contents are more 
difficult to mobilize. (Dreifuss, 1975; Barnea et al, 1977 1 Israel et 
al, 1979). It has been suggested (Sachs and Haller, 1968) that the readily 
releasable pool consists of granules located in close proximity to the 
plasma membrane which discharge their contents following membrane 
depolarization. Newly synthesized hormones may first enter the 
readily releasable pool before equilibrating with the storage pool. 
Although peptidergic neurons are not morphologically different from f 
the classical neurotransmitter there appears to be a difference in 
the mode of replenishing the released substance (Hokfelt et al,1980). 
Thereis apparently no synthesis of peptides in the nerve terminal 
nor has any reuptake of released peptide been demonstrated. In contrast, 
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neurotransmitter concentrations in the nerve terminal are kept fairly 
constant by / efficient replacement of released transmitter by (i) 
enzymatic synthesis in the nerve terminal (ii) reuptake from the 
synaptic cleft (iii) supply of neurotransmitter (or precursors) 
in secretory vesicles from the cell body via axonal tranaport (Iversen, 
1978: Hokfelt et al, 1980). 
The final stages of the neurosecretory process can be divided into 
at least 4 stages: 
( ;) . . (; ;) 2+ h 1 b L Depolarization LL Ca transport across t e p asma mem rane 
(iii) transport of the secretory vesicles to the plasma membrane 
(iv) fusion and exocytosis. 
/ 
2+ Depolarization and the role of Ca in neurosecretion will be discussed 
in detail. 
(i) DEPOLARIZATIOH 
There is a high concentration of K+ ions within nerve cells and a low· con-
+ centration of Na ions, relative to the extracellular concentration of 
l 
these ions. + This distribution of cations results from Na -ions being pumped 
d + . +/ + out an K ions into the cell by the Na K A'JP ase pump •. Also, the plasma 
+ membrane of the nerve 4 ce1l at rest is much more permeable to K -ions than 
it is to Na+ ions. Thus, more positive ions are pumped out of the cell than 
into it. Since most of the intracellula:t;' aniol\S (phosphate, sulphates and 
protein ions) are nondiffusible the negative cha:t;'ges remain wit~in the 
cell which becomes electronegative re\ative to the outside (whic~ is electro-
positive). Thus a potential difference of - 70 mV is formed accross the 
plasma membrane. Nerve cells are unique in that they, can propagate 
an action potential. The first event is an increase in the 
') 
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+ . . + . . Na permeability, causing Na ions to move into the cell 
neutralizing the negative charge. This leads to furthe r opening 
' 
of adjacent Na+ channels and propagation of a wave of depolarization. 
This is followed by an increase in K+ permeability as the Na+ 
permeability returns to normal. The efflux of K+ ions re-establishes 
the charge difference across the membrane. Then the K+ permeability 
decreases back to normal and there is active outward transport 
of Na+ ions across the cell membrane (Guyton, 1976). 
Depolarizatipn of nerve cells in vitro can be effected via several 
mechanisms: 
(i) Electrical stimulation 
+ + (ii) Ouabain is known to inhibit the Na /K dependent ATPase and 
thereby cause membrane depolarization (Skou,1965). However, if 
this were so, intracellular Na+ would be expected to increase- and 
+ intracellular K decrease. There is evidence that the intracellular 
Na+ remains unchanged and that the effect of ouabain is via changes 
+ in the K ion concentration (Verity et al, 1979). 
(iii) Veratridine and associated alkaloid compounds induce 
depolarization by opening Na+ channels and allowing an influx 
of Na+ .(Ohta et al, 1973). 
(iv) Since the plasma membrane is relatively permeable to K+ the 
presence of high extracellular K+ perturbs the transmembrane potential, 
+ h . . . d K enters t e neuron, neutralizing the negative charge an thus 
inducing depolarization. This effect is not blocked by tetrodotoxin 
(a specific Na+ channel blocker) indicating that the mechanism of 
action of K+ induced depolarization is not mediated via the opening 
+ 
of Na channels. It is usually assumed that the depolarizing 
action of high K+ ions ·simulates neuronal excitation. However, 
at the neuromuscular junction, raised extracellular K+ -concentrations 
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or an electric current have been shown to depolarize nerve terminals. 
It has been demonstrated while the depolarizing curr ent actually reduced 
the amount of transmitter released from the nerve terminal, the 
increased K+ concentration had the opposite effect. This difference 
suggests that K+ ions may influence transmitter release via a 
·mechanism distinct from depolarization (Gage and Quastel, 1965; 
Cooke and Quastel, 1973). Moreover, incubation in a constant level 
of high K+ ions does not produce pulsatile action potentiali as 
electrochemical gradients cannot be re-established (Somjen, 1979). 
(v) Ionophores have been shown to depolarize membranes. The ionophore 
2+ 2+ A23187 transports Ca and Mg across the plasma membrane (Reed and 
Lardy, 1972). This rapid ca2 + influx mimics, in part, the events 
preceeding the neurosecretory event. Ionophore X537A binds mono and 
divalent cations. 2+ In the absence of extracellular Ca , X537A 
stimulates vasopressin release from the isolated neurohypophysis· while 
A23187 is without effect (Nakazato and Douglas, 1974). The greater 
effectiveness of the ionophore X537A is attributed to its ability 
to transport monovalent cations, thereby causing depolarization 
(Cochrane and Douglas, 1975). 
(ii) ROLE OF CA2+IN NEUROSECRETION 
Ca2+ entry into the nerve terminal is thought to be essential for 
.. 
neurosecretion. Resting nerve cells are impermeable to Ca2+ The 
arrival of the action potential at the nerve terminal leads to an 
increased permeability and consequent influx of ca2+ (Rahamimoff and 
Abramovitz, 1978) which is a function of the membrane potential (Douglas, 
19 7 4) Th . 11 1 . 2 + . . . e intrace u ar concentration of Ca rises from a resting le~ei 
-8 -5 2 + 
of 10 M to 10 M free Ca Calcium is known to cross the piasma 
membrane via at least 2 channels (Baker, 1972): 
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(i) + the initial entry via a Na related channel and 
( ~~) . 2+ LL the subsequent entry via a voltage dependent Ca channel. 
The rise in intracellular ca2+ is the predominant trigger for the 
initiation of fusion of the synaptic vesicles with the synaptic 
plasma membrane and the subsequent release of neuropeptides. This 
process has been termed stimulus-secretion-coupling (Douglas 1975). 
ca
2+ is thought to surround the synaptic vesicles near the synaptic 
plasma membrane, causing a rearrangment of the water soluble 
components of the plasma membrane resulting in a spontaneous membrane 
fusion (Llinas, 1977). Exocytotic release from the vesicles may 
or may not involve. the loss of the entire vesicle contents. Acher 
(1979) postulated that the entire vesicle contents are released 
in neurohypophyseal secretion. 
A number of mechanisms are involved in lowering the elevated intra-
cellular Ca~+ concentration (Rahamimoff and Abramovitz, 1978). 
(i) at Ca 2+ concentrations of 10-6M or greater, intraterminal 
mitochondria will take up calcium, 
(ii) Ca 2+ can be buffered by binding to cytoplasmic proteins eg. 
calmodulin (Ch~ng, 1980). 
(iii) ca2+ extrusion from the nerve cell in a Na+ dependent manner, 
(iv) diffusion of Ca2+ from the nerve terminus. 
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THE ROLE OF NEUROTRANSMITTERS IN CHEMICAL TRANSMISSION 
=============================-===========-- -----------
Chemica l transmission across the synapse involves transmitter synthesis, 
storage , release, reaction with the receptor and termination of 
transmitter actions. 
The first step 1.n chemical transmission is the synthesis of the transmitter 
? molecules 1n the nerve terminals. Each neuron can usually only synthesize 
one specific transmitter. The transmitter molecules are manufactured 
de nova as a precursor molecule which then undergo a series of enzymatic 
reactions. The transmitter molecules are stored in the axon terminal 
in synaptic vesicles. There may be thousands of synaptic vesicles 1.n 
each nerve terminal, each containing tens of thousands molecules of 
transmitter. 
Release of the transmitter is initiated by the nerve imp4lse increasing 
the permeability of the nerve terminal to calcium ions which activates 
the release mechanism. The actual mechanism of release is still 
controversial. Some groups believe that the synaptic vesicles fuse 
directly with the presynaptic membrane and discharge their contents 
into the synaptic space, while others believe that there is a mobile 
pool Qf transmitter molecules liberated through special channels. 
The released transmitter molecules interact with specific receptor 
sites in the post synaptic membrane. Many transmitter receptors 
have two functional components: a binding site for the transmitter 
and a pore passing through the membrane that is selectively permeable 
to certain ions. The binding of the transmitter to the receptor causes 
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a conforma tional change of the binding site which opens the pore in 
the membrane a llowing ions to flow down their concentration gradients 
into or out of the cell. This results in an increase or decrease of 
the neuron firing rate. 
Some transmitters are inactivated by enzymes in the synaptic space 
eg. acetylcholinesterase destroys acetylcholine. Others, such as 
noradrenalin are taken up and destroyed by enzymes in the nerve 
terminal while othzrs are recycled and stored in the synaptic vesicles. 
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PURPOSE OF STUDY 
The hypothalamus is an important tissue regulating a wide 
spectrum of physiological processes in vertebrates • Nevertheless, 
many aspects of the basic biochemistry and physiology of secretion 
of the hypothalamic peptide hormones remai~ unknown. One of the ~-
most important aspects of the regulation of hypothalamic peptide 
hormone secretion is the so called negative feedback by end organ 
hormones. 
The purpose of this thesis was to establish indices which could be 
used to monitor the viability of the incubated hypothalamus. Once 
established, this provided a system to study the factors affecting 
LHRH and IRS release from the hypothalamus. Studies on the nature 
of the feedback mechanisms of steroids on LHRH release were initiated. 
To date it has been difficult to assess factors controlling LHRH 
release from the hypothalamus in vivo as it is secreted in nanomolar 
amounts and once secreted, is rapidly degraded (t! = 6 minutes in 
blood). However, taken in conjunction with in vivo pretreatment 
4 
of animals, the incubated hypothalamus provides an in vitro system 
for studying the physiological and biochemical end organ feedback 
regulation as well as short loop feedback and/or autoregulation 
of the hypothalamus. 
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2. MATERIALS AND METHODS 
• 
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2. 1. Ma t erials 
The sources of peptides used are as follows: 
6 10 LHRH and D-leu -desGly LHRH ethylamide, Ayerst Laboratories; 
_ovine LH, NIH (Bethesda , USA); Tyr 1-somatostatin, a gift from 
Dr. D,Coy (New Orleans, USA); somatostatin-14, neurotensin and 
substance P, U.C.B. bioproducts peptide department (Bruxelles); 
13-endorphin, leu-and met-enkephalin, Beckman; TRH, Calbiochem; 
vasopress1.n, Parke-davies Laboratories; oxytocin, Sandoz Laboratories. 
The following reagents were obtained from Sigma Chemical Co. 
(St. Louis); L-DOPA, dopamine, noradrenalin, adrenalin, 
acetylchloline, histamine, serotonin, melatonin, GABA(t·"-''''~b.it~,,,e,OtldJ,1113-
• ~ -'f( b . 
oestradiol, testosterone, EGTA, TPCM, TLCM, oua ain, cytochaiasin 
1 cyclohexamid~ and : actinomycin ,D.The sources of other reagents 
are as follows: 125~ '. N1:3-I (IMS 30) and Piil amino acid 
hy<lrolysate (TRK 440)7 Radio chemical centre (Amer sham UK); 
carboxymethyl cellulose (CM 32), Whatman (Kent, U.K.); verapamil 
(Isoptin), Knoll AG (Ludwigshafen); X537A, Hoffman le Roche Inc. 
(Nutley N.J.); A23187, vincristine and vinblastine Eli Lilley 
laboratories (Indianapolis, Indiana). 
~ TPGM '. N-oL-tosyi -ph2ny/abn_yi chb,omd'no.re ; TL.c.M '. N-{-tO!>~l- l-{!JSjl c.h\o,..on-etha~. 
Antiserum 774 used for the radioinnnunoassay of immunoreactive 
somatostatin was a gift from Professor,A,Arimura (New Orleans, 
U.S.A.) 
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2.2. METHODS 
2. 2. 1 
2.2.2 
/ 
2.2.3 
ANIMALS 
Male Long-Evans rats (250-350g) were kept on a 14:10 
light : dark cycle in a humidity and temperature controlled 
room with food and water available ad libitum. Each 
experiment was commenced at 9.00 am to avoid possible 
differences in diurnal hypothalamic content and secretion 
of LHRH and somatostatin (kerdelhue et al, 1978). 
ISOLATION OF THE HYPOTHALAMUS 
Rats were decapitated and the hypothalamus (including the 
median eminence)removed within 1-2 mins. The area dissected 
out extended from the anterior edge of the optic chiasma 
to the mammillary body, 1.5 - 2.0 mm from the midline .and 
approximately 2-3 mm in depth. The dis~ction was carried 
" 
out with a razor blade to ensure the cleanest cut possible 
with the least damage to the tissue (Fig. 2,.1). 
INCUBATION OF THE HYPOTHALAMUS 
The hypothalami were pre-incubated in Wasserman tubes 
in 1.0 -ml of Hanl<'s physiological medium (pH 7 .4) which 
contained JO-3M bacitracin to prevent peptidase degradation 
of LHRH and somatostatin (McKelvy et al, 1976). For storage 
purposes the incubation medium contained the antibiotics 
penicillin, neomycin and streptomycin (PNS) each at a 
concentration of 5 ml/L. After 45 min of preincubation 
the hypothalami were washed twice, transferred, and the 
incubation continued for 60 min in Wasserman tubes containing 
0.5 ml medium (pH 7.4) which contained JO-3M bacitracin, 
IO uCi of tritiated amino acid <"[~n] amino acid hydrolysate) 
and the appropriate substance(s) to be tested. The incorporation 
of [ 3Hjamino acids into tissue reflected the ability of the 
tissue to synthesize proteins which was then used as an 
index of tissue viability. Both the pre-incubation and the 
incubation were carried out with continuous shaking at 37°c 
in an atmosphere of 95% o2 and 5% co2 • 
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Fi7e hypothalami were used in each treatment group and 
all experiments were repeated more than once for confirmation 
of results. 
After the 60 min incubation period, the hypothalami were 
removed and the incubation medium stored at 4° for+ 2 h 
prior to measurement of LHRII and somatostatin immunoreactivity. 
ESTIMATION OF PROTEIN SYNTHESIS 
The hypothalami were washed once to remove the radioactivity 
from the outside of the tissue, and homogenized in 2 ml of 
cold distilled water in a Potter-Elvehjem homogenizer (clearance 
,135 nnn). O. 2 ml of this homogenate was transferred to a 
Wasserman tube containing 0.2 ml of cold IM perchloric acid 
(PCA)and the protein precipitated by centrifugation at 2000g 
for 5 min at 4°c. The precipitate was washed three times with 
cold 0.5M PCA and the supernatants thereof, pooled. Scintillant 
(5 ml Dimulene) was added to the precipitate dissolved in 
200 µl H2o and to the pooled supernatants, and the radio-
activity was assessed (Beckman ~ scintillation counter). 
The degree of incorporation of amino acids into the hypothalamic 
tissue was taken as an index of protein synthesis and tissue 
viability. ·. W1~1n C\h~ ty-eoJ~ 9roup rlOl"\-Ylo11ht~ /.<l()S cllar~ ,nc:11~ 
bl1 on ob VIOV6 d,~ '" eHJart'liro atAq lna>Yf'Dt'c,.t~ . 
TISSUE EXTRACTION 
To determine the tissue content of LHRH and somatostatin, 
the remaining hypothalamic homogenate (1.8 ml) was extracted 
in 2N acetic acid and the suspension was centrifuged at 
12500 xg for 30 min at 4°C in a Sorvall RC2B centrifuge. The 
supernatant was decanted, lyophilized and stored unde.r vacuum 
in a dessicator.Lyophilised extracts were reconstituted in 
phosphate buffered saline containing gelatin (0.04M phosphate, 
0.15 M sodium chloride, O.OJ M disodium ethylene diaminotetra-
acetic acid, 0. )7. sodium azide, pH 7.0 and 0.1% gelatin (BDH)) 
(PBS gelatin) for assay of LHRH and somatostatin 
immunoreactivity. 
2.2.6 
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ESTIMATION OF OXYGEN CONSUMPTION 
0 l b h h h 1 Was measured at 37oc xygen upta ce y t e ypot a amus 
with a Clarke-type electrode (YSl Mode l 53 oxygen monitor, 
Yellow Springs Instrument Company, Ohio). The hypothalami 
were incubated,with continuous agitat ion,in 4 ml Hank's 
medium and the o2 uptake r_ecorded . The medium was replaced 
every 15 min over a period of 3h to ensure an adequate 
supply of o2 and glucose to the tissue. 
o2 uptake was calculated according to the following equation: 
Oxygen uptake : p atoms /min= units/min 
xlOO 
where units/min= slope of the curve read from the recorder 
chart paper which was marked O to 100 uni ts. 
= x-y where xis the pen deflection when 
the electrode was equilibrated with air 
saturated buffer. 
y is the pen deflection when oxygen tension 
in the buffer= 0mm Hg (anaerobic) 
Oxygen concentration (x 100 ) in the medium at 37°C is taken 
as 235 µ moles/L 
µ atoms o2/ml = 0,235 x 2 = 0,470 
V = volume of the incubation medium . 
... 
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2.3 RADIOIMMUNOASSAY OF LHRH 
The method of radioimmunoassay (RIA) used was a modification 
of that described by Hendricks et al (1975). 
LHRH ANTISERUM 
Antiserum 1076 was produced in this laboratory by conjugation 
of LHRH (_ Ayerst Laboratories) to keyhole 
limpe t haemocyanin by carbodi-imide condensation (Hendricks et al, 
1975). Since there are no free COOR groups in the LHRH molecule, 
condensation must take place between a -NH2 group of the decapeptide 
(e.g. Gly-NH2) and a COOR on_ the haemocyanin molecule. The specificity 
of the antiserum 1076 is affected by changes in the middle of the 
peptide (residues Ser4 to Leu7) and differences in the NH2 and 
COOR termini of the molecule are not affected. It therefore seems 
l 'k 1 h h . f . . . . 2 8 10 i e y tat t e site o con3ugat1on is at His , Arg, Gly .. 
This antiserum (1076) showed no cross reaction with any of the 
neurotransmitters, hypothalamic or pituitary peptides tested except ( 
for~ endorphin which was shown to interfere in the radioimmunoassay. 
The antiserum 422 (gift from A.Arimura) was produced to LHRH 
adsorbed on polyvinylpyrrolidone. This antiserum is directed 
toward both the NH2 and COOR termini and it is anticipated that it 
will not detect conformational changes in ·· the middle portion of 
the decapeptide. 
RADIOIODINATION OF LHRH 
Synthetic LHRH (Ayerst ~aboratories)was labelled with 
using a modification of chloramine T method of Greenwood and Hunter 
(1963). • 
LHRH ASSAY PROTOCOL 
Standards were prepared in solutions identical in composition 
to that in which peptide release was assayed. 100µ1 of standard 
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(in double dilution from 625 - 1 pg) or 100 µl of sample was added 
to glass Wasserman tubes containing 200 µl PBS - gelatin buffer, followed 
by the addition of 100 µl of diluted antiserum with mixing (initial 
dilutions 1076, 1:20,000; 422,1:1 1000), Gelatin was added to the buffer 
to lessen the number of counts adsorbing to the walls of the glass tubes. 
1251 The assay was preincubated at room temperature for 20 min, 100 pl 
LHRH ( rJ 10,000 cprn) added and the assay incubated overnight at 4°C. 
. 125 Separation of free LHRH from antibody bound · I - LHRH was achieved by 
the addition of 750 pl dextran (0,05%) coated charcoal (Sigma Chemical 
Company). The assay was incubated for 15 min at 4°C, centrifuged at 
1000 x g for 15 min at 4°C, the supernatant decanted and the bound 1251-
LHRH counted in a Beckman auto-gamma counter. A typical standard curve using 
antiserum 1076 is shown in Fig. 2.2. The intra-assay co-efficient of 
variation was 7.3% and the inter-assay co-efficient of a variation was 
4.4%. 
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FIG 2.2 
Displacement of 1251-LHRH bound to antiserum 1076 by increasing 
amounts of synthetic LHRH. Binding of l25r-LHRH to antiserum (B) 
is expressed as a percentage of the total l25r-LHRH (T) added (B/T x 100). Each point represents the mean of two determinations 
+ lS. D. 
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2.4 RADIOlMMUNOASSAY OF SOMATOSTATIN 
A radioimmunoassay for somatostatin (based on the method of 
Arimura et al (1975(b)) was developed in this laboratory. 
SOMATOSTATIN ANTISERUM 
Antiserum 774 (gift from Arimura) was produced by immunizing 
sheep with cyclic somatostatin-14 conjugated to human serum 
gannna globulin. The antiserum showed no cross reaction (<.,O.01 %) 
with any of the neurotransmitters, hypothalamic a;nd/or pituita);'y 
peptides tested. Cross reaction with somatostatin analogues was 
tested and it was demonstrated that while the antiserum can 
tolerate changes at the N-terminal end of the peptide the cyclic 
conformation ·of the peptide is essential for antibody binding 
indicating that the antigenic site is directed towards the Phe 6 ~Tr1/ 
po~tion of the molecule. Although the specificity of antiserum 774 
has been demonstrated, in view of the recent findings that somatostatin-._ 
14 and a 3K immunoreactive species are released from stalk median 
eminence synaptosomes (Kewley,1981) it seems unlikely that only sol_Ila,-
tostatin-14 is released from the incubated hypothalamus. To embrace this 
possibility the term innnunoreactive somatostatin has been U$ed 
throughout this thesis. 
RADIOIODINATION OF SOMATOSTATIN 
Somatostatin does not contain a tyrosine residue and thus cannot 
be iodinated. Therefore, an analogue of somatostatin with tyrosine 
substituted for alanine at the 1 position (NH2 terminus) was used 
for iodination (tyrosylated somatostatin, a gift from D.Coy) 
(Coy et al 1973) • 
... 
Initially, radioactive somatostatin was produced using the 
chloramine T method of Greenwood and Hunter (1963), with purification 
of 1251 - tyrosylated somatostatin on CM, -32. However, radioactive 
.somatostatin produced by this method showed poor innnunoreactivity 
and rapid deterioration. A solid phase lactoperoxidase method 
for somatostatin iodination was developed which produced a stable 
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radioactive somatostatin. To 5µg of tyrosylated somatostatin in 
JO·.ul of Q.OJM HCL in a glass vial (0.5 x 1.5 cm) were added: 
20 µ1 of 0.5M phosphate,3 pl of solid phase lactoperoxidase 
(prepared according to Karonen et al (1975)) and 1.5mCi of t 25 r 
(IMS30,Radiochemical Centre, Amersham). The reaction was 
initiated by the addition of 300 ng of hydrogen peroxide in 5 pl 
of water. After 15 min with occasional finger flicking a further 
300 ng of hydrogen peroxide was added. After 30 min, JOO pl of O.Ol~ 
sodium phosphate pH 7.4 was added and the reaction mixture was centrifuged 
at JOOOg for 3 min to precipitate the eolid phase lactoperoxidase. 
The supernatant was applied to a CM32 cation exchange column 
equilibrated with 0,002M ammonium acetate,pH4.6. Iodide damaged 
peptide eluted with 0.2M anmionium acetate,pH 4.6 (approximately 
50 mls) and iodinated somatostatin was eluted with 0.5 M 
ammonium acetate,pH 4.6 (Fig.2.3). Fractions containing the 
125 
main peak of . I - tyrosylated somatostatin were pooled, 
aliquoted into vials coated with 1.0% BSA to minimise 
adsorption of label on the walls of the vials and stored at 
-20°C. 
PROTOCOL FOR SOMATOSTATIN ASSAY 
Standards were prepared in solutions identical in composition 
to that in which peptide release was assayed. 100 pl of 
standard (double dilutions from 5000-1.2 pg) or JOO pl of 
sample was added to Wasserman tubes containing 200 pl of PBS-
gelatin buffer follied by JOO pl of Ab 774 (initial dilution 
" 
1:16000). The tubes were shaken and preincubated at room 
l25 t:o • 
temperature for 2 hr• JOO µl of . I-tyrosylated sorri'1.statin 
( ..... JQOOO cpm) was added and the tubes incubated overnight at 
0 }25 4 C • Separation of the free I - tyrosyl.at.ed. somatostatin 
4 
125 from antibody bound . I - tyrosylated somatostin was achieved 
with dextran-coated charcoal as described in the LHRH assay. 
1251 . . The bound - tyrosylated soma_~ostatin was counted in a Beckman 
auto-garrnna counter. A typical standard curve using antiserum 
774 is shown in (Fig.2,4). The intra-assay coefficient of 
variation was 9.2% and inter-assay coefficient of variation 
was 15.7%. 
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FIG 2.3 
1 . f'l f 125 I . . E ution pro i e o I- Tyr - somatostatin - 14. Sequential 
elutions with 0.002 (l),0.02 (2) and 0,5M (3) annnonium acetate 
buffers pH 4.6 are indicated. Peak I represents free Na125r, 
peak II showed poor innnunoreactivity and is assumed to represent 
intermediate groducts, peak III showed good inununoreactivity and 
represents 12 I- Tyrl - somatostatin - 14. 
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FIG 2.4 
Displacement of 1251 - [Tyr 1J - somatostatin bound to antiserum 
774 by increasing amounts of synthetic somatostatin-14. Binding 
of l25r - Tyrl - somatostatin -14 (B) to antiserum is expressed 
a-s a percentage of the total 1251 - Tyrl - somatostatin-14 (T) 
added (B/T x 100). Each point represents the mean of two 
determinations+ 1 S.D. 
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2.5 STATISTICAL METHODS 
The following statist ical analys e s of data were performed 
using a Hewftt Packard HP 32E calculator: 
2.5.1 
2.5.2 
2.5.3 
2.5.4 
2.5.5 
Mean 
X 
n 
where x = the observations 
f = the sum of 
n = number of observations 
Standard deviation 
where n< 30 
Standard error of the mean 
s EM -- S.D 
'1 n 
Coefficient of variation 
= S.D. X 100 
X 
Levels of significance were calculated according to the 
students t-test (Finney, 1964). Values of p (probability) 
were de t ermined from appropriate tables (in Giba-Geigy). 
When p ~ 0. 05 the difference between sample and cor.h-ol 
were regarded as not significant. 
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2.6 COUNTING OF RADIOACTIVITY 
GAMMA EMITTERS 
125 d' . . d . d . I -ra 1.oact1.v1.ty was eterm1.ne 1.n an autogannna 
spectrometer. A Beckman Gamma 310 system (efficiency 
""'"75%) was used, in which samples were counted for 2 min 
or to a preset error of 5%. 
~ETA EMITTERS 
PH1radioactivity was determined in a Beckman liquid 
scintillation system LS-233 (counting efficiency [3H] 
,.., 32%). Samples were dissolved in 5 ml Dimilume - 30 
(Packard)and counted for 10 min or to a preset error 
of 5%. 
• 
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3. INVESTIGATIONS INTO THE OPTIMUM CONDITIONS FOR 
INCUBATION OF THE HYPOTHALAMUS IN VITRQ 
- 57 -
INTRODUCTION 
In order to study the control of release of neuropeptides 
from incubated rat hypothalami it was first necessary to 
establish conditions for the viable maintenance of isolated 
hypothalami in culture. 
Several reports of incubation systems for isolated hypothalamic 
tissue have been described (Bennett et al, 1975; McKelvy et al 1976; 
Rotszte jn et al, 1976; Berelowitz et al, 1978; Bigdelli and 
Snyder, 1978; Sundberg and Knigge, 1978; Negro-Vilar et al, 1978; 
Sheppard et al 1 1979). 
In these studies the conditions necessary for the maintenance 
of biochemically functional hypothalami in vitro were not 
thoroughly investigated. 
We had previously observed tha.~ on prolonged incubation, LHRH release 
increased markedly presumably due to tissue necrosis and leakage 
of the peptide from neurons. It was therefore important to select an 
incubation period which maintained the viability of the tissue· 
and yet allowed adequate time for test substances to take effect and 
for sufficient neuropeptide release to occur. 
In this section an examination of the effects of medium, temperature 
and time on hypothalamic release of LHRH has 
been undertaken. A number of indices of functional viability have 
been employed: 
]. Protein snythesis is an index of hypothalamic viability 
as it is dependent on a wide spectrum of biochemical pathways 
as well as the maintenance of subcellular integrity. 
2. The ability of the hypothalamus to utilise oxygen. 
3. The ability of the hypothalamus to release LHRH and somatostatin 
in the presence of depolarizing concentrations of K+ (60mM). 
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In initial experiments, LHRH was undetectable in all incubation 
media used. This could be accounted for by the concomitant 
release of degrading peptidases known to be present in · the 
hypothalamus (Griffiths and Kelly, 1979). Bacitracin (an antibiotic), 
has been shown to inhibit LHRH degradation by peptidases extracted 
from the hypothalamus (McKelvy et al, 1976). Thus the ability of 
bacitracin to prevent the breakdown of hypothalamic LHRH released into 
the incubation medium was tested. 
3. l O METHODS 
The first studies were directed at determining the most suitable 
medium, temperature and time for the incubations. 
3.1.1. 
3.1.2. 
3.1.3. 
Hypothalami were dissected from rats within 1-2 mJ_ns of death 
as described in Chapter 2 
In initial studies the hypothalami were innnediately . placed 
in Hank's Earle's or Eagle's Minimal Essential Medium (MEM) 
(Table 3. 1 ). LHRH release from and LHRH content of the 
hypothalami were monitored at intervals over a period of 3h. 
To determine the appropriate concentration of bacitracin 
which adequately inhibited LHRH degradation, hypothalami 
were incubated in Hank's medium for 3h at 37°C. Aliquots 
(100 pl) of this medium were added to tubes containing 
-10 000 cpm 1251- LHRH and increasing concentrations 
of bacitracin (J0-7M to 10-2M). After a further incubation 
at 37°c for 3h the peptidases were inactivated by boiling 
and the amount of undeagraded 1251~ LHRH determined by 
binding to excess LHRH antiserum (~ 1076). 
To establish the most suitable temperature of incubation 
for the system, the release of LHRH from and the LHRH content 
0 0 0 
of, the isolated hypothalamus at 11 , 27 and 37 C was measured. 
Hypothalami were incubated in Hank's medium containing bacitracin. 
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TABLE 3. 1 1'":0MPOSITION OF INCUBATION MEDIA 
HANK'S .. EARLE'S 
g/L g/L 
NaCL 8.00 6.80 
KCL 0,40 0,40 
CaC1 2 0, 14 0.20 
Mgso4.7H20 0.10 o. 10 
MgC12.6H20 o. 10 
.,.. 
Na2HP04"2H20 0.06 
NaH2P04H20 O.J 25 
KH2Po4 0.06 
Glucose 1.00 l .00 
Phenol Red 0.02 Q.05 
NaHC03 0.35 2.20 
_Gas Phase Air Air/co2 
PNS 5ml/L 5ml/L 
Bacitracin IO-3M JO-3M 
EAGLE'S MEM 
Amino Acids mg/L Vitamin mg/L 
L-. Arginine HCL 126.4 ,D-Ca-Pantothen~te J.O 
L-Cysteine 24.0 Choline Chloride 1.0 
L-Glutamine 292.0 Folic Acid 1.0 
L-Histidine HC1.2H20 41.9 i-inositol 2.0 
L-Isoleuc.ine 52.4 Nicotinamide 1.0 
L-lysine HCl 73 .1 Pyridoxal rICl 1.0 
L-Methionine 14.9 Riboflavin 0. l 
L-Phenylalanine • 33.0 Thiamine HCl J.O 
L-Threonine 47.6 
L-Tryptophan 10.2 
L-Tyrosine 36.2 
L-Valine 46.8 
Eagle's MEM was made up in Hank's medium contain~ng 5ml calf serum and 0.5ml 
PNS. The pH of Hank's and Earle's media was pH 7. Eagle's MEM was made up 
in Hank's medium (without NaHC03) containing 5ml calf serum and 5ml PNS 
The pH was adjusted to 7,6 with bicarbonate. 
3.1.4. 
3.1.5. 
3.1.6, 
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To select a suitable incubation period at 37°c, hypothalami 
were preincubated for 45 mins in 1 ml of Hank's medium. The 
hypothalami were washed twice and incubated for up to 150 min 
in Hank's medium containing rHJ amino acid hydrolysate 
(Radiochemical Cente, Amersham). At 30 min intervals 
during the incubation,LHRH release from and amino acid 
uptake by hypothalamic tissue and amino acid incorporation 
into protein was recorded. 
Oxygen utilisation by the hypothalamic tissue incubated 
in Hank's medium at 37°C was measured with a Clarke Electrode. 
In experiments where K+ stimulation of LHRH release was used 
as a Griterion of functional viability, hypothalami were 
preincubated (see Chapter 2) and then placed in Hank's 
medium with and without 60 mMK: 
The incubation was continued for 60 min and the release of 
LHRH into the medium and protein synthesis by the tissue 
was recorded. 
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3.2. RESULTS 
3.2.l, 
3.2.2. 
3.2.3. 
3.2.4. 
The LHRH content of the hypothalami remained unchanged 
during a 3h incubation in Hank's and Earle's media (Fig 3.1 ). 
In Eagle's MEM hypothalami c LHRH content decreased to 
undet ectable levels during the incubation period (Fig.3,1 ), 
Consequently Hank's medium was used in all subsequent studies. 
In the absence of bacitracin, release of LHRH from the 
isolated hypothalamus was undetectable in all of the 
incubation media (results not shown). 
. -5 
At a concentration of 10 M, bacitracin gave 60% inhibition 
of catabolic peptidase activity. Concentrations of 10-4M 
bacitracin, and greater, gave complete inhibition of LHRH 
degradation (Fig. 3.2 ). In all subsequent experiments in which 
the incubation medium contained IO-3M bacitracin, the released 
LHRH and IRS could be detected in the medium, 
During a 3h incubation period the basal release of LHRH 
from hypothalami in culture was low at 11°c (25.8 :!: 4.7 pg/hypoth.) 
and increased at 27°C (272 + 32 pg/hypoth.) and 37°C (310 :!: 52pg/ 
hypoth.) (Fig. 3.3 ). In all further experiments, incubations 
were· carried out 37°c. 
The rate of LHRH release from andPH]amino acid uptake by the 
hypothalami remained constant during the first 90 min of 
incubation(:!: 47pg LHRH/h and 600000 cpm respectively). 
However protein synthesis declined after 60 min (Fig. 3.4 ). 
During the final 60 min of incubation, loss of cell viability 
and peptide leakage was suggested by the reduction in both 
protein sythesis and amino acid uptake and the large increase 
in LHRH release. In view of these findings in all 
subsequent experiments the incubation period was limited 
to 60 min following a 45 min preincubation period. 
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INCUBATION TIME (hrs) 
Effect of incubation medium on hypothalamic LHRH content. 
Hypothalami were incubated for 3 h in Hank's ( ...__., },Earle's 
(~ ) and Eagle's minimal essential medium (MEM) ( & & ) 
LHRH content was significantly less in MEM at 2h (p<0.05) and 
3h (p<0.0001). Values are means + SEM, n=4. 
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FIG 3.2 
Inhibition of degradation of exogenous LHRH by bacitracin. 
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FIG 3.3 
Effect of temperature on LHRH release (pg) and LHRH content (ng) 
in the rat hypothalamus. 
Hypothalami were incubated in Hank's medium for 3h. Values are 
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3.2.5 
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The rate of oxygen consumption stabilised during the 
preincubation period and remained constant for the 
duration of the 60 min incubation period (Fig 3, 5 ) • 
Thereafter oxygen consumption declined concomitantly 
with the decline in protein synthesis and increased 
LHRH release. 
The third criterion of viability was the K+-stimulated 
2+ 
release of LHRH and IRS from hypothalami. The Ca 
dependence of the K+- stimulated release of both 
neuropeptides was demonstrated (See Results: Chapter 4) 
• 
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FIG 3.5 
Hypothalamic oxygen consumption in Hank's medium. Hypothalami were 
incubated in Hank's medium (4 ml2 at 37°C. The incubation medium was 
replaced at 15min intervals. 
- 68 -
3.3 DISCUSSION 
.( 
In the present study, conditions were established for the 
maintenance of isolated rat hypothalami in vitro. for a 
period of 60 min. Protein synthesis, amino acid uptake, oxygen 
consumption, low basal release of neuropeptide and the ability 
to K+-stimulate neuropeptide release from the hypothalami during 
this period were taken as indices of the functiona l viability 
of the system. 
However, other studies of release from isolated hypothalami have 
not established optimal conditions for viability. It has been 
reported that fragments of hypothalamus remained viable for 7-13 
days!.!!~ under carefully controlled conditions (Hirooka 
et al, 1978). Bradbury et al, (1974) has found that during an 
incubation period of 3 h the incubated hypothalami showed 
considerable metabolic activity and maintained a reasonable 
electrolyte balance. However there was evidence of histological 
damage to the tissue at the end of this incubation period. 
This agrees with the present observation of a decrease in 
protein synthesis, oxygen consumption and amino acid uptake and a 
great increase in LHRH release after incubation for periods 
longer th~n 60-90 min. 
The reason for the inability to detect any LHRH in the hypothalami 
incubated in Eagle's MEM is not known. Degradation of the neuropeptide 
within the intact subcellular compartments was not expected. 
Hypothalami incubated in Hank's medium or Earle's medium were 
able to maintain the hypothalamic LHRH content during the incubation 
period. 
• 
Release of LHRH from incubated hypothalami was found to be 
a temperature dependent process. Moreover, the K'"!:..stimulated 
release of the neuropeptides was Ca2+ dependent. This is taken 
as indirect evidence that the basic functional properties of the 
hypothalamus are preserved under the present experimental conditions. 
In the absence of bacitracin, LHRH release could not be demonstrated. 
This could be due to: 
(I) degradation by peptidases which are known to be in the 
hypothalamus and may be secreted concomitantly with the 
neuropeptide. 
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<2) reupta!~e of the neuropeptide. 
(3) inhibition of release of the neuropeptide by released 
neurotransmitters and the same or other neuropeptides. 
(4) no release occurring. 
Bacitracin inhibited the degradation of 1251 -LHRH at 10-4M and 
greater concentra tions. Although the inhibition of degradation 
f ' d. d d. d h 125 d o non-io inate LHRH was not stu ie , t e I -LHRH was prepare 
by a method shown to produce biologically active peptide (Marshall 
and Odell, 1975). Moreover, after incubating hypothalami in medium 
containing I0-4M bacitracin, LHRH release could be demonstrated. This 
suggests that bacitracin acts by inhibiting peptidase degradation of 
LHRH rather that bacitracin itself stimulating LHRH release from the 
hypothalamus in a non-specific manner. Surprisingly in other studies 
in which bacitracin was not included in the incubation medium 
(Rudenstein et al, 1979) LHRH release was apparently even higher 
than in the present study. These high estimates may, in part, be due 
. d d d . f 125 ' h d. ' to pepti ase egra ation o I -LHRH int era ioimmunoassay, 
thus causing a reduced binding to antibody and a consequent overestimate 
of LHRH release. 
In all incubations hypothalamic LHRH content remained unchanged, 
suggesting that although protein synthesis occurs, no net detectable 
biosynthesis of LHRH is taking place. These observations contradict 
those of Sundberg and Knigge, (1978). who used a similar incubation 
system but noted an increase in hypothalamic LHRH content. These 
differences could have been due to the specificity of the antisera 
employed in the radioimmunoassays and their relative interaction with 
LHRH, LHRH fragments and putative prohormonal LHRH. Antiserum 1076, 
used in this study1 requires residues Ser
4 to Leu7 of LHRH for effective 
binding and recognises both putative prohormonal LHRH and decapeptide 
LHRH (Millar et al, 1977). Thus a conversion of prohormonal LHRH 
to LHRH might not show much increase in innnunoreactivity using 
antiserum 1076. If the antiserum used by Sundberg and Knigge was 
specific for decapeptide LHRH, the net 1.ncrease in innnunoreactivity 
might reflect conversion of prohormonal LHRH to LHRH without 
necessitating de novo biosynthesis. To resolve this issue, 
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we reassayed the LHRH content of incubated hypothalami using 
antiserum 422 which interacts poorly with prohormonal LHRH 
since it requires both N and C terminus of LHRH for binding 
(see Chapter 2). Again no net increase in LHRH irrnnunoreactivity 
was noted (results not shown). 
In view of the present findings in subsequent experiments hypothalami 
were first preincubated for 45 min and then incubated for 60 min in 
Hank's medium containing JO-3M bacitracin, in a 95% o2 , 5% co2 
h 37oc. atmosp ere at 
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4 . THE ca2+ REQUIREMENTS OF LHRH AND IRS RELEASE FROM 
THE INCUBATED RAT HYPOTHALAMUS . 
• 
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...... 
INTRODUCTION 
High concentrations of K+ depolarize excitable plasma membranes 
and lead to the secretion of neurotransmitters (Mcilwain, 1952) 
(Jones and Mcllwain, 1979). The secretory process is dependent 
on the extracellular calcium, which apparently enters the nerve 
terminus after the depolarising event (Blaustein et al, 1977). 
The present section describes studies on the release of LHRH 
and IRS from incubated rat hypothalami in the presence of 
d 1 • . d h f C 
2+. h epo_arising agents an t e role o a int e secretory event. 
Depolarization of peptidergic nerve terminals is thought to result 
+ 
in an increase in the passive permeability to Na prior to or in 
2+ 
conjunction with an increase in the Ca entry. (Thorn et al, 1978). 
Na+ is required for the generation and propagation of action 
potentials but it is not essential for the release process in vitro 
(Dreifuss et al, 1971 ; Dreifuss, 1975; Hartter and Ramirez, 1980). 
. + . . 
The release of hormones can occur in Na free solutions and in 
the presence of tetrodotoxin which blocks Na+ channels (Douglas, 1964). 
In the presence of 60mM KCL,K+ ions flow freely through the 
membrane and neutralise the intracellular net negative charges 
thus stimulating the depolarization event. A calcium dependen~ 
K+-stimulated release of LHRH and IRS from hypothalami has been 
shown (Rotsztejn et al, 1976; 1977, 1978; Berelowitz et al, 1978; 
Bigdeli and Snyder, 1978; Negro-Vilar et al, 1978, 1979; Sheppard 
et al, 1979; Drouva et al, 1980; Maeda and Frohman, 1980; Richardson 
et al, 1980; Hartter and Ramirez, 1980). 
C 
·Ouabain has been used as an alternative method of inducing 
membrane depolarization (Bigdeli and. Snyder, 1978; Hartter and 
Ramirez, 1980). This may provide a more physiological approach 
to investigate depolarization as it is effective without the 
+ 
addition of non-physiological concentrations of K. 
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To investigate the role of ca
2+: in the neurosecretion of peptides, 
the effect of the carboxylic ionophores X537A and A23187 on the 
release of LHRH and IRSfrom incubated hypothalami was studied 
In addition to their known depolarizing action both ionophores 
2+ 
transfer Ca across the cell membrane (Cochrane and Douglas, 1975). 
The less specific ca
24 ionophore,X537A,is a more effective 
depolarizing agent due to its ability to transfer monovalent cations, 
+ + particularly Na and K, across the cell membrane down their 
concentration gradients. 
Verapamil specifically blo.cks Ca2+ channels (Malaisse et al,1977). 
Thus, incubation of the isolated hypothalamus with this substance, 
in the presence of either A23187 or X537A may assist in differentiating 
the direct role 9f Ca21- from that of a depolarizing effect of cations 
in ionophore-induced1 neuropeptide release. In the present investigations 
K: ouabain and the ionophores X537A and A23187 were used to induce 
2+ Ca release of neuropeptides from the hypothalamus. The calcium 
requirements for and the effect of verapamil on the induced r~lease 
of LHRH and IRS was studied • 
• 
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4. I , METHODS 
Hypothalami,dissected as previously described,were pre incubated 
in 1 ml of Hank's medium for 45 min. Thereafter they were 
incubated in 0.5 ml of Hank's medium for 60 min. All test 
substances were added at the beginning of the 60 min incubation 
period. In depolarization experiments 60 rnM KCL or 10 pM 
ouabain was present in the incubation medium. In other 
1 experiments ca2 + was omitted from the medium and 0.5mM EGTA 
. 2 + 
added to chelate any free Ca . The ionophore X537A or 
A23187 was present at a concentration of lµM or lOpM. When 
present, the concentration of verapamil was 20pM. At the end 
of the incubation period the release of LHRH and IRS into the 
medium was assayed and uptake and incorporation of[3H]· amino 
acid hydrolysate by the hypothalamic tissue were monitored 
(See Chapter 2). 
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4.2 RESULTS 
In the presence of Ca2 : addition of 60 mM KCL or JO pM 
ouabain to the incubation medium stimulated LHRH and IRS 
release from the incubated hypothalami (Fig. 4. I, 4. 2 ) , 
2 + 2 + However, in the absence of Ca (Ca -free medium and 0.5 mM EGTA), 
60mM KCL failed to stimulate the release of LHRH and IRS 
from the incubated rat hypothalami (Fig. 4.1, 4.2 ). 
Basal release of both neuropeptides was also decreased in 
2+ 
the absence of Ca . Verapamil (20 pM) completely inhibited 
K+- stimulation of LHRH release but only partly inhibited 
IRS release (Fig. 4. I , 4. 2 ) • 
The ionophores X537A and A23J87 were added to the incubation 
medium at a final concentration of lµM since highe~ levels 
(lOpM) inhibited protein synthesis (results not shown). 
Ionophore X537A increased LHRH and IRS release from incubated 
rat hypothalami (Fig. 4. 3, 4. 4 ) . 
This ionophore-induced release of LHRH was completely blocked 
by verapamil while IRS release was only partially reduced 
(Fig. 4.3, 4.4 ). Ionophore A23187 reduced LHRH release 
under all conditions (Fig, 4.3 ). IRS release was 
2.+-enhanced in the presence of this ionophore and Ca . This 
effect was not blocked by verapamil (Fig. 4.4 ). 
However A23187 did not induce IRS release from hypothalami 
. b d . 2 +f d' i_ncu ate in Ca ree me ium. 
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2
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4.3, DISCUSSION 
+ AK (60rnM) - stimulated release of IRS was consistently 
demonstra ted. It was not always possible to produce K+-
stimulated release of LHRH from the incubated hypothalamus. 
However, when K+-stimulated release of both hormones was 
demonstrated it was invariably greater than that shown with 
ouabain. This is in agreement with the results of Bigdeli 
and Snyder, (1978). 
2+ 2+ · + In the absence of Ca (Ca -free medium and 0. 5 mM EGTA) K -
stimulation was not effective and there was a decrease in 
the basal release of both hormones. Sheppard (1980) 
.___demonstrated that the addition of 0.5mM EGTA to t~ medium 
+ --decreased basal IRS release and prevented K -stimulated release 
of this neuropeptide. However, as the author still retained 
2.5mM ca2+in the medium, this would mean that l 5mM free 
'l+ 
ca' was still present. Since this concentration is similar 
\ 
2+ 
to the physiological concentrations of free Ca , these findings 
are somewhat perplexing. 
2+ The present results suggest that there are differences in the Ca -
dependence of the release of the two peptides. Verapamil completely 
inhibited the K+-stimulated release of LHRH but only partially 
inhibited IRS release. This suggests that IRS release is, in part, 
independent of ca2+ entry into the nerve terminal or that different 
2+ . . . . . . . Ca ·channels are involved which are insensitive to verapamil. The 
results clearly point to differences in the release mechanism for 
the two neuropeptides. Differential release of LHRH and IRS 
has been replicated in synaptosomes (KewleY, 1981). 
In the presence of 1pm ionophore the viability of the incubated 
hypothalamus was maintained as indicated by protein synthesis 
and [ 3H]-amino acid uptake. 
The release of LHRH from the incubated rat hypothalamus induced 
by X537A may be analagous to that produced by depolarization. The 
inhibition of this release by verapamil implicates the involvement 
of extracellular calcium which enter the nerve terminal in 
the presence of ionophore. 
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A23187 was unable to stimulate LHRH release. It is possible 
that: 
(I) the two ionophores differ in their mode of action at the 
nerve terminal. 
Mg2+ 2+ (2) A23187 may promote entry (Reed and Lardy, 1972). Mg 
1.s .known to inhibit the neurosecretory process (Thorn et al I 978). 
' 
(3) the ca2 + influx induced by A23187 may be a continuous rather 
than a transient effect. This could resemble a pathological 
condition in which there 1.s disruption of the ion permeability 
barriers (Schlaepfer, I 977). 
(4) , A23187 may enter the peptide neuron and mobilise intracellular · 
2+ Ca (Brown et al, I 980). 
Differences in the mechanism of action of the two ionophores 
is exemplified by the IR 'S results. Verapamil did not inhibit 
X537A-induced release of IRS and in fact, enhanced A23187-induced 
2+ 
release. However, there was inhibition of IRS release in Ca -
free medium in the presence of A23187. This implies that extracellular 
2+ Ca~ is essential for the ionophore-induced release. The ionophore 
2+ 
may, nevertheless, induce the formation of Ca channels which are 
insensitive to the action of verapamil. 
The differential effects of K+-stimulation,the ionophores X537A 
and A23187 and verapamil,on the release of LHRH and IRS from the 
2+ incubated rat hypothaJaimus point to differences in the Ca -
requirements for the release of the two neuropeptides . 
... 
5. 
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THE ROLE OF PROTEIN SYNTHESIS, PROTEOLYTIC ENZYMES AND 
THE MICROTUBULAR AND MICROFILAMENTOUS SYSTEM IN THE RELEASr; 
OF LHRH FROM THE INCUBATED RAT HYPOTHALAMUS. 
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INTRODUCTION 
In the classical mode l of neuronal peptide biosynthesis and 
secretion it has been postulated that the peptide is first 
synthesized as a precursor molecule via ribosomal mechanisms 
in the cell body and then packaged into secretory granules 
where post-translational cleavage to the peptide products 
occur. The secretory granule is transported down the axon 
and is stored at the nerve terminal prior to release 
(Gainer and Brownstein, 1978). It is debatable whether 
the microtubular and microfilamentous systems play a role "in 
neuropeptide release. There is evidence that colchicine, 
vinblast.ine and vincristine do not play a direct or functionally 
important role in release (Rufener et al, 1972; Russell and 
Thorn, 1973). Cytochalasin B, however, has been shown to decrease 
release of hormones (Douglas and Sorimachi, 1972), but since 
it is also known to interfere with gluco.se uptake and utilisation 
it is thus debatable whether its action involves microfilaments 
in the release process or whether exocytosis is dependent on 
glycolysis in the conditions studied (Dreifuss, 1975). Neverthe-
less, there are reports that colchicine, vinblastine and 
vincristine decrease release of several hormones by interfering 
with the roicrotubule system (Williams and Wolff, 1971; Labrie 
et al, 1973). 
In order to determine whether LHRH has similar biochemical 
and subcellular processing, the effects of inhibitors of 
~ . . . protein synthesis, proteolytic cleaving enzymes and the micro-
tubular and microfilamentous system on its release were investigated. 
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5. 1. METHODS 
These experiments were conducted before optimization of the system. 
Rats were decapitated and the hypothalami were rapidly dissected 
as previously described. The hypothalami were incubated 
for 3h at 37°c in Hank's medium containing either [ 3H]-amino 
acid hydrolysate as an index of protein synthesis or[.3H]-uridine 
as an index of RNA synthesis. To differentiate the effect of 
inhibiting protein synthesis at either the transcription or 
translation stage, the incubations were carried out in the 
presence of actinomycin D and cyclohexLmide (200 µg/ml or 
1000 pg/ml). To decrease protein synthesis indirectly, potassium 
cyanide (SmM) and sodium azide (SmM) were added to the medium. 
The trypsin inhibitor, N-«-tosyl-1-lysyl chloromethane (TLCM) 
and the chymotrypsin inhibitor N-C(-tosyl-phenylalanyl chloromethane 
(TPCM), were added at a concentration of 200 pg/ml. 
In a separate study inhibitors of the microtubular and micro-
filamentous system, colchicine (100 pg/ml), vinblastine (100 pg/ml), 
vincristine (100 pg/ml) or cytochalasin _B (100 pg/ml) were . 
added to the medium. 
In each experiment the release of LHRH into the medium, the LHRH 
hypoth~lamic content and the uptake and incorporation of (:H~ 
amino acid hydrolysate or [.3H] uridine by the hypothalamic 
tissue were determined, at the end of the incubation period. 
(See Chapter 2). 
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5.2 RESULTS 
Cyclohexumide and Actinomycin D decreased protein synthesis of 
the incubated rat hypothalamus. Actinomycin D caused a greater 
decrease and was effective at lower concentrations (Table5.l ). ~ 
RNA synthes is, as monitored by incorporation of (:1~-uridine 
into PCA precipitabie RNA wa.s surprisingly impaired with both 
treatments ( 6-oddc.,..-d, 191g ). LHRH release from the incubated 
hypothalamus was decreased by inhibitors of protein synthesis 
/ 
in a dose dependent manner (Table 5.1 ). 
Moreover, there was a close correlation between the degree of 
inhibition of protein synthesis and the degree of decrease in basal 
release of LHRH. The hypothalauiiccontent of LHRH and the uptake 
of [ 3~-amino acid. hydrolysate (Table 5. 1 )and [ 3H]-uridine (Godda.,·d, 
l~lS. ) were unaffected by inhibitors of protein synthesis. 
KCN and NaN3 decreased protein synthesis concom
itant with a marked 
increase in LHRH release from the hypothalami . TLCM did not effect 
the release or hypothalamic content of LHRH. TPCM was also without 
effect (Table 5_. ~) ,However both inhibitors caused a marked iecrease 
in protein synthesis in the tissue but neither affected the uptake 
of the [?~-amino acid hydrolysate by the hypothalamic tissue 
(Table 5.2 ). 
None of the tested inhibitors of the cytoskeletal system inhibited 
LHRH release (Table 5.3) 
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TABLE 5. I 
Effect of Inhibitors qf Protein Synthesis on LHR,H Release 
- -
from the rat hypothalamus in vitro 
-
.. 
.. 
Additions LHRH release LHRH Incorporation Uptake 
(%) hypothalamic PCA ppt, PCA spn. 
content (%) (%) •, 
. . . . " . 
... " . 
(%) 
. . . . . . . . ' . 
. . . . . . . . . . . . ... . . 
. . . . . . .. . .. .
 . . . ... 
Nil JOO + 7 100 + 8 100 + 6 100 + 7 
- -
- -
Actinomycin D 
(200 µg/ml) 56 + JS ~ 93 + 6 42 + JO xx 94 + 0. I 
-
- -
-
Actinomycin D 
(1,000 pg/ml) 42 + 14 xx 96 + 6 42 + 8 xx . 97 + 2 
- -
- -
Cyclohex~mide 
(200 pg/ml) 98 + 13 94 + 3 8J + 8 JOJ + 8 
-
- -
-
Cyclohexi..mide 
(1,000 µg/ml) 65 + 10 X 93 + 6 55 + 7 X 95 + 9 
-
- -
-
.... 
" 
Values are means + SEM (n = 4)_ 
X p<0~005 xx p <0.0001 . The rema~n:Lng data were not 
significantly different from control release results (p> 0.05}. 
' 
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TABLE 5.2 
Effect of Protease Inhibitors on LHRH Release from the rat 
hypothalamus in vitro 
Additions LHR.H rele.a,se LHRH J:ncorpora, tion 
(%) hypothalamic PCA ppt. 
content. (%2 
(%) 
Nil 100 .+- 17 JOO i 6 JOO + 8 
TLCM (200 µg/ml) 95 + 21 86 + 8 JS+ 10 ,t'X 
- - -
TPCM (200 µg/ml) 91 + 18 137 + 5 18 + 9 xx 
-
-. 
. . . . . . . . . . . . . . . .. 
Values are means + SEM. (n = 4)_ 
xx p<0.0001. The remaining data were not -' s;i_gn;i.ficantly different 
from control release results (p>0.05). 
Uptake 
PCA spn;· 
(%1 
JOO .+- 8 
92 + 3 
-
95 + 4 
-
. . . . 
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TABLE 5.3 
Effect of Inhibitors of Microtubule and rlicrofilame
nt Contraction 
on LHRH Re lease f rom the rat hypothalamus ·in vitro 
Additions LHRH relea.se LHR,H 
;[nco;rpox-a.t~on 
(%) hypothalamic PCA ppt 
content (%) 
(%) 
. . . . . . . . 
' . 
. . . . ' . ' . 
. . . . . 
. . . . . . 
.. . . ...
.. .. ...
. 
Nil JOO + 5 JOO + 14 
JOO .r J 2 
-
-
Colchicine 
( 100 µg/ml) 109 + 2 80 + 6 ]08 + ]3
 
-
-
-
Vinblastine 
(100 µg/ml} JJ3 + 9 JJ4 + 8 62 + JQ X 
-
Vincristine 
( l 00 µ,g/ml) 95 + 6 105 + 13 102 + 7 
-
-
Cytochalasin B 
(100 p,g/ml) 106 + 2 1 J 5 + 9 92 + 9 
-
-
-
. . . . . . .
 ' . . . . 
. 
. . . . . 
. ~ . . . . . . 
. . . . . . . 
. . . 
Values are means + SEM. (n == 41. 
Uptake 
PCA spn. 
(%2 
.... 
. . . . . 
. . . . . . . 
JOO + 6 
-
J08 + 2 
-
]03 + 2 
-
l 1 l + 5 
-
99 + 3 
-
. ....
. 
x p<0.005. The remaining data were not signi~~can
tly d~fterent from 
control release results (p>0.05). 
·, 
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5. 3 • DISCUSSION 
In thepresence of inhibitors of protein synthesi s there was a 
decrease in LHRH release from the incubated hypothalamus. The 
hypothalamic LHRH content was unchanged. Thus, it appears that 
LHRH destined for secretion is either synthesized de novo or 
·the neurosecre tory process itself is directly or indirectly 
dependent on the synthesis of proteins. When protein synthesis 
was inhibited indirectly by inhibition of oxidative phosphorylation 
LHRH release increased markedly. This suggests loss of cellular 
integrity with the consequent release of cellular hormone content. 
The failure of typsin/chymotrypsin inhibitors to effect secretion 
of LHRH would appear at first sight to argue against the postulate 
that putative prohormonal LHRH is cleared to LHRH by a tryptic-
like enzyme (Millar et al, 1978). Clearly the chemicals entered ? 
the cell as protein synthesis was impaired, However, trypsin 
inhibitors have also been shown to be ineffective in inhibiting 
conversion of proinsulin (Steiner et al, 1967) and _pro PTH 
Kemper· et al, 1972) by endogenous tryptic-like enzymes. 
This suggests that the specificity of these enzymes are different 
from that of trypsin. Alternatively, the inhibitors may not enter 
the secretory granules in which cleavage occurs. It is also 
possible that large stores of decapeptide LHRH are present in the 
hypothalamus and that inhibition of cleavage of newly synthesized 
prohormone will have little effect on the amount released (Fink, 1979). 
Millar (personal conrrnunication) has demonstrated that prohormonal 
LHRH in sheep and rat hypothalamus constitutes less than 1% of the 
total LHRH. 
Vincristine, vinblastine and cytochalasin B did not inhibit the 
release of LHRH from the incubated hypothala~i. This suggests 
that release is not dependent on the microfilament/microtubule 
system which is sensitive to these drugs, or that the rate of 
complex formation between the tubulin and drugs is slow and is 
longer than the incubation period (Wilson et al, 1974). 
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£.: THE EFFECT OF NEUROTRANSMITTERS ON LHRH AND IRS RELEASE 
FROM THE INCUBATED RAT HYPOTHALAMUS . 
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INTRODUCT'J:ON 
The abundance of neurotransmitters in the ME and other hypothalamic 
regions has been well documented and numerous physiological studies 
have implicated them in the regulation of anterior pituitary function 
II (Muller et al,1977) . In this chapter only the regulation of LH/FSH 
and GH secretion by neurotransmitters will be discussed. The central 
noradrenergic systems exerts an important stimulatory effect on LH 
secretion (Krulich,1979). The serotoninergic system is generally 
thought to inhbit LH secretion while the role of the ~opaminergic system 
remains controversial although it does influence LH secretion 
(Mueller et al,1976; Drouva and Gallo,1977; Vale et al,1977; Kruli~h,1979). 
The central noradrenergic, serotoninergic and dopaminergic systems 
all appear to have a stimulatory role in GH secretion in primates 
(Krulich, 1979). However,some controversy exists as to the exact physiological 
role of dopamine . in rat GH secretion (Vij ayan et al, 1978). No e_vidence 
is available to implicate a direct effect of biogenic amines on 
pitutary LH/FSH or GH secreting cells. Thus,many of the neurotransmitter 
effects on pituita.ry secretion may be mediated · via their influences 
on the secretory activity of the hypothalamic peptidergic neurones . . 
Noradrenalin, dopamine, acetylcholine and serotonin have been localised 
II 
to nerve terminals in the stalk median eminence (Muller et al, 1977). 
Somatostatin ~nd LHRH are also present in nerve endings close to 
II 
the capillary loops of the hypophyseal portal system (Hokfelt et al, 
1974). Axo-aXo.nic contact of LHRR and dopamine containing nerve terminals 
has been demonstrated in close proximity to the portal vessels 
(Aj ika, 1979). This morph:> logical evidence further supports the concept 
of synaptic influence of neurotransmitters on the release of 
hypothalamic neuropeptides which regulate pituitary hormone secretion • 
.. 
Direct experimental evidence of neurotransmitter mediated release 
of LHRH and somatostatin from the hypothalamus has been derived from 
in_vitro experiments. A dopamine~induced release of LHRH from 
hypothalamic nerve terminals (synaptoro .mes) has been reported by 
Bennett et al (1975). Subsequently dopamine-and noradrenalin-
induced release of LHRH from hypothalamic fragments and the isolated 
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hypothalamus was demonstrated (Rotsztejn et al, 1976, 1977; Negro-
Vilar et al, 1978, 1979; Ojeda et al, 1979). The effect of the 
catecholamines on LHRH release is apparently steroid dependent 
since it was only observed on ME fragments from intact and not 
castrated rats. Thus the effect of a neurotransmitter could be 
modified by the sex,endocrine status and age of the experimental 
animal. In addition the dopamine and noradrenalin release of 
LHRH from the ME could not be demonstrated from hypothalamic fragments 
which included the arcuate and ventromedial nuclei(Negro-Vilar et 
al,1979). This suggests that the release of LHRH from ME terminals 
is tonically inhibited by neurones with cell bodies located in 
the MBH. Such recurrent inhibitory or facilitatory neural circuits } 
may play an important role in the modulation of LHRH release into 
the portal vessels. 
Dopamine and noradrenalin have been reported to stimulate somatostatin 
release from hypothalamic tissue in vitro (Negro-Vilar et al, 1978; 
Maeda and Frohman,1980). Somatostatin release from rat hypothalamic 
synaptosomes was stimulated by dopamine (10-6M) (Wakabayashi et al, 1977). 
However, Bennett et al (1979) showed that dopamine, noradrenalin 
and serotonin did not increase somatostatin release from rat hypothalamic 
synaptosomes. The stimulatory effects of dopamine and noradrenalin 
on somatostatin release are difficult to align with their effects in vivo. 
However, it is possible that there is a simultaneous stimulation of 
GRF release which overrides the inhibitory effect of somatostatin 
on GR release. 
To try to elucidate the effects of neurotransmitters on the release 
of LHRH and Eomatostatin from rat hypothalami,the following experiments 
were conducted in our laboratory concurrently with experiments utilising 
synaptosomes isolated from ovine stalk ME. This should distinguish 
effects taking place at the nerve terminal from those which require 
the intact,integrated neuronal circuits present in the whole 
hypothalamus. The effect of a wide range of biogenic amines (I0-7-10-5~) 
on the LHRH and IRS release from the incubated hypothalamus was studied. 
6. 1. METHOD 
Hypothalami, dissected as previously described,were preincubated 
for 45 min in 1 rnl of Hank's medium. The incubation was continued 
for 60 min in 0.5 ml ·Hank's medium containlng . the- particular 
neurotransmitter (JO-SM or I0-7M). Vitamin C (5 x I0-4M) was added 
to the incubation medium as an antioxidant. Preincubation with 
the neurotransmitter did not enhance the response. At the end 
of the incubation period the release of I.HRH and IRS into themedium 
was assayed. Incorporation and uptake of the {:HJ-amino acid 
h/rolysate by the hypothalamic tissue was monitored (see Chapter 2). ·, 
"' 
• 
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6.2. RESULTS 
LHR.t~ release was increased by melatonin and decreased by GABA 
(Table 6. 1 ). Serotonin, noradrenalin, adrenalin, L-DOPA, 
dopamine, acetylcholine and histamine were without effect 
on LHRH release from incubated rat hypothalami. 
IRS release w~s increased. by melatonin, serotonin and adrenalin, 
and decreased by histamine (Table 6.1 ). Noradrenalin, L-DOPA, 
dopamine, acetylcholine and GABA were without effect on IRS 
release from incubated rat hypothalami. 
- ~.':> -
TABLE 6. 1 
Effect of neurotransmitters on LHRH and IRS release from the incubated 
rat hypothalamus 
Additions LHRH release IRS Release 
% of control % of control 
nil 199 + 11 i . 100 + 3 
L-DOPA 97 + 5 120 + 12 
Dopamine 110 + 4 110 + 9 
Noradrenalin 100 + 11 94 + 10 
Adrenalin 87 + 6 215 + 4 
Histamine 100 + 5 61 + 8 
-
Serotonin 85 + 9 190 + 2 
Melatonin 180 + 12 xx 171 + 3 
GABA 52 + 11 100 + 2 
Acetylcholine 93 + 4 103 + 5 
Concentration of all neurotransmitters 10-
7M, similar 
results were obtained at concentrations of 10-
5M. 
Results are expressed as mean+ SEM, n=5. 
x p<O. 005, xx p<0.001. The rema1.n1.ng data were not 
xx 
:~x 
xx 
xx 
significantly different from control release results (p>0.05) • 
• 
I ... - --· .:-• --- ,.. . ---.• 
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6. 3. DISCm,SION 
LHRH release was stimulated by melatonin in accordance with 
the results of Kao and Weisz (1977) . who reported a similar 
finding. Since melatonin has been found to have anti-
gonadotrophic actions when administered to rats (Karnberi, 1973) 
these findings appear paradoxi"cal. It is · clear from the present 
results that melatonin does not inhibit LHRH release. Melatonin, 
,also increased LHRH release from SME syna,ptosomes (Kewley, 1981). 
Taken in conjunction with the present results it appears that 
this indolamine exerts a stimulatory effect at the LHRH ME 
nerve terminal. 
GABA decre~sed LHRH release ~n keeping with the inhibitory role 
of this neurotransmitter. GABA causes a selective increase 
in permeability of the plasma membrane to chloride ions, thus 
tending to stabilise the membrane potential which would prevent 
a depolarisation induced release of neuropeptide. 
IRS release was stimulated by melatonin, serotonin and adrenalin. 
This has not previously been reported. Melatonin also increased 
IRS release from SME synaptosomes while serotonin and adrenalin 
were without effect (Kewley, 1981).The _physiological significance 
of the increase in IRS release by the indolarniries · cannot be 
explained at present. The increase in IRS release attributed 
to adrenalin is in accordance with the low plasma GH levels 
observed during an intravenous infusion of adrenalin (Hertelendy 
et al, 1969). The inhibitory response of histamine on IRS release 
has noc previously been reported and is of interest in view of 
the fact that few substances have been shown to inhibit IRS 
release. The physiological significance of this finding cannot 
* however, be explained. 
Dopamine and noradrenalin have been reported to stimulate LHRH 
and somatostatin release from the isolated hypothalamic tissue 
(Rotsztejn et al, 1976, 1977; Ojeda et al, 1979; Negro-Vilar et al, 
1978, 1~79; Maeda and Frohman, 1980). HoweverJon 6 separate 
occasions we were unable to show any significant effect of these 
catecholamines on LHRH and IRS release from the incubated hypothalamus. 
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Since other neurotransmitters effected the release of 
LHRH and IRS the lack of effect of the catecholamines cannot 
be accounted for by 1an ineffective rate of diffusion and 
uptake into the hypothalamus. The differences 1n response 
may be due to the videly different incubation conditions 
used. It is also possible that the sex, age and endocrine 
status of the rats used in the present experiments influenced 
the LHRH release in response to the catecholamines (Vale et al, 1977}. 
Interactions between peptidergic and nonpeptidergic neurons 
II 
almost certainly occurs within the hypothalamus (Muller et al, 1977)_. 
In addition, some peptidergic neurons are known to contain 
a classical neurotransmitter as well e.g. substance P and 
serotonin are present in the same neuron in rat medulla 
II 
oblongata (Hokfelt et al, 1980}. 
Thus,a neurotransmitter released from a peptidergic nerve 
terminal may feedback on the same neuron: to regulate secretion 
in addition to the ·conventional synaptic contact between neurons. 
In the present chapter we have clearly demonstrated that some 
biogenic amines do influence the release of LHRH and IRS from 
the incubated hypothalamus. These data are ·compatible with the 
concept that LH/FSH and GH release from the pituitary may be 
modulated by monoamine regulation of hypothalamic LHRH, IRS and 
GRF secretion. 
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7. THE EFFECT OF NEUROPEPTIDES ON LHRH AND IRS RELEASE 
FROM THE INCUBATED RAT HYPOTHALAMUS • 
• 
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. INTRODUCTION 
Neuropeptides are known to influence the release of anterior 
pituitary hormones and it is thought that they may affect the 
release of other neuropeptides (Vale et al,1977; Moss,1979). 
Substance P, neurotensin, TRH, LHRH, somatostatin, VIP, CCK, 
the enkephalins, vasopressin and oxytocin, have been localised 
" within nerve terminals (Hokfelt et al,1980). However, a neuro-
transmitter role has only been thoroughly substantiated for 
substance P C Krivoy et al· 197.9), 
The hormones of the gastro-intestinal tract, gastrin, gluc~gon, 
insulin, substance P, VIP, CCK, secretin and ~ombesin are -also 
present in the CNS· (Krieger and Liotta, 1979; Zimmerman, 1979). 
Likewise, somatostatin, neurotensin and the enkephalins originally 
found in the brain have since been localised in the gut. Thus, 
apart from,or together>with their hormonal function of peptide 
release into the general circulation these hormones may have 
additional neuromodulator or neurotransmitter roles within the CNS. 
Extensive maps for the distribution of substance P, enkephalins, neurotensin, 
CCK and bradykinin have been published but it is still not clear 
whether two or more neuropeptides can reside in a single neuron 
·11 . 
(Hpkfelt et al1 1980). There is evidence to suggest that ACTH 
and~ endorphin are present in the same neurons in the hypothalamus 
(Block et al, 1978;Watson et al ,1978), Recentl~,, Hgkfelt et al ( 1980hrnve 
observed TRH-like immunoreactivityin substance P neurons in the rat 
medulla oblongata. Thus it is apparent that a peptidergic neuron 
may contain not only a classical neurotransmitter but also other 
neuropeptides exemplifying the complexity of the neurosecretory 
process. 
Met-enkephalin stimulates GH and inhibits LR release in vivo 
(Beaumont and Hughes,1979; Drouva et al,1980). However, it is 
not clear whether these effects are mediated at the hypothalamic 
+ 
or hypophyseal level. Recently, met-enkephalin inhibition of K 
stimulated LHRH and somatostatin release from MBH fragments was 
demonstrated (Drouva et al, 1980). Thus regulation at the 
hypophyseal level could account for alteration of the pituitary 
release of LR and GH as reported i~ ~ (Beaumont and Hughes , 1979). 
This section describes the effects o.f a wide range of neuropeptides 
(200- 500 ng/ml) on the release of LHRH and IRS from incubated 
rat hypothalami. These experiments were undertaken to see whether 
other neuropeptides modulated the release of LHRH and IRS 
and thus,indirectly>the release of the associated trophic 
hormones from the pituitary. 
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7. I • METHODS 
Hypothalami, dissected as previously described (See 
Chapter 2 ·) were pre-iucubated for 45 min in 1 ml of Hank's 
medium. The incubation was continued for 60 min in 0.5 ml 
Hank's medium containing the particular neuropeptide (200-500 ng/ml). 
Release was not enhanced when the hypothalami were preincubated 
with neuropeptides. 
At the end of the incubation period the amount of LHRH and 
IRS released into the medium was assessed by radioirrnnunoassay. 
Incorporation and uptake of ~H]-,amino acid hydrolysate 
by the hypothalamic tissue was also monitored (See Chaper 2) • 
• 
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7.2 RESULTS 
The basal release of LHRH from the incubated hypothalamus 
was decreased in the presence of vasopressin and oxytocin 
(Tabl e 7.1). LHRH release appeared to be enhanced by ~-endorphin. 
However , these high values were due to interference of ~-endorphin 
in the LHRH radioimmunoassay. LHRH r elease was not altered 
by TRH 1 somatostatin-I4, neurotensin, substance f, met-enkephalin 
and leu-enkephalin Table 7.1). 
The basal release of IRS was increased by TRH, LHRH, neurotensin 
and substance P (Table 7.1). IRS was not altered by vasopressin 
oxytocin, met-enkephalin, leu-enkephalin, and ~-endorphin . 
... 
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TABLE 7. 1 
Effect of neuropeptides on LHRH and IRS release from 
incubated rat hypothalami. 
LHRH RELEASE 
ADDITIONS % CONTROL 
Control 100 + 6 
-
Substance p 92 + 7 
-
Neurotensin 104 + 9 
-
TRH 102 + 4 
-
LHRH -
SS-14 101 + 3 
-
Met-enkephalin 93 + 10 
-
Leu-enkephalin 108 + 5 
-
Vasopressin 61 + 9 * 
--
Oxytocin 66 + 9 * 
-
p-endorphin -
Concentration of all neuropeptides 500 ng· /ml 
Results are expressed as mean .:!:. SEM n = 5 
IRS RELEASE 
% CONTROL 
100 + 5 
-
173 + 5 
** 
-
125 + 5 * 
-
189 + 2 
** 
-
250 + 15 
** 
-
-
100 + 3 
-
93 + 7 
-
107 + 5 
-
89 + 9 
-
110 + 10 
-
* p < 0. 005; ** p < 0. 001. The ·remaining data were not 
significantly different from control release results 
(p ) o. 05) 
- 1U4 -
7. 3 DISCUSSION 
Vasopressin and oxytocin both caused a decrease in LHRH release. 
Pavel et al (1979) reported that the plasma LR level was not 
affected by intraventricular administration of either vasopressin 
-3 -4 -
or oxytocin (IO - 10 M). However, AVT · (arginine vasotocin) 
-4 • I • ( 1 O pg) decreased plasma LR level suggesting .- ·- that this effect 
is mediated by inhibition of LHRH release from the hypothalamus 
by interference with serotonin transmission in the brain. Our 
results suggest that oxytocin and vasopressin have a direct 
inhibitory effect on LHRH release which is not consistent with the 
in vivo effects of Pavel. 
Higher concentrations of oxytocin and vasopressin (500 ng/ml) were 
used in the present experiments to facilitate penetration of the 
neuropeptide into the tissue. It is possible that oxytocin 
and vasopressin mimic the effects of AVT. However,it seems 
unlikely that the effects seen are mediated via serotonin, 
since LHRH release from the incubated hypothalamus was insensitive 
to serotonin. 
Neither oxytocin or vasopressin had any effect on IRS release 
indicating that the observed result was a specific effect on 
LlL.1Ul release. 
Neurotensin and substance P both increased IliS release from the 
incubated hypothalamus. These results are in -agreement with those 
of Sheppard et al (1979) and Maeda andfrohman (1980) .and 
• further support the suggestion that the decrease in serum GH and TSH 
levels following intraventricular injection of substance P or 
neurotensin is due, at least in part, to a stimulation of hypothalamic 
somatostatin release (Rivier et al,1977; Chihara et al, 19789 
Maeda and Frohman 1978). In this laboratory, it has been sho~"ll. that 
substance P increased the basal release of IRS from ovine SME 
+ 
synaptosomes whereas neurotensin decreased the basal and K -stimulated 
release of somatostatin (Kewley, 1981 , ) • 
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Taken in conjunction with the present findings, this suggests 
that there are stimulatory receptors for substance Pon the 
somatostatin nerve terminals of the somatostatin neuron. In 
contrast, neurotensin binding receptors at the nerve terminal 
of somatostatin neurons are inhibitory. Thus, the stimulatory 
effect of neurotensin on the intact hypothalamus may override 
the inhibitory effect of this neuropeptide on somatostatin release 
from the nerve terminal. This suggests that at least two receptor 
sites for neurotensin exist on the intact neuron. 
It has been suggested that met-enkephalin can modulate the release 
of the peptides by interacting with a specific opiate receptor located 
on LHRH and somatostatin neurons. Met- and leu-enkephalin did not 
effect the basal LHRH and IRS release from incubated hypothalami 
in agreement with Rotsztejn et al (1978) ·and·· sheppard ~et al (1979(a)). 
These findings all report the effect of the enkephalins on basal 
release of neuropeptides from the incubated hypothalamus. It 1s 
possible that met-enkephalin failed to penetrate the tissue. 
However, it seems more likely that the opiates only effect the 
stimulated release of neuropeptides. Met-enkephalin significantly 
decreased the K+ - stimulated release of LHRH and somatostatin 
from MBH fragments (Drouva et al, 1980). These results suggest 
that met-enkephalin can modulate release of neuropeptides by 
intereacting with a specific opiate receptor found on LHRH and 
somatostatin neurons. Alternatively, met-enkephalin may effect 
LHRH and somatostatin release indirectly by inhibiting dopamine 
secretion. The latter is known to stimulate release of LHRH and 
somatostatin from the incubated hypothalamus (Rotsztejn, 1976, 
1977, 1978; Negro-Vilar et al, 1978; Berelowitz et al, 1980}. 
Met-enkephalin also inhibited the K+-stimulated release of IRS 
from ovine SME synaptosomes (Kewley, 1981). This suggests that 
inhibitory receptors for met-enkephalin exist on the nerve terminals 
of somatostatin neurons. 
Central administration of TRH has been reported to inhibit GH 
secretion (Chihara et al, 1976). 
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The stimulatory action of TRH on IRS release from the incubated 
hypothalamus in the present experiments provides an explanation 
for the effect cf the neuropeptide on GR secretion. Somatostatin 
was · reported to inhibit TRH release from organ cultures of rat 
hypothalami (Hiraoka et al~1978; Hollander et al)1980). Together 
these in vitro results suggest a possible short-loop feedback 
system operating in the hypothalamus which may be an additional 
factor 1.n modulating the hypothalamic-pituitary-th ,'Yroid axis. 
An interesting finding, is the increased release of a IRS in the 
presence of LHRH, but the physiological relevance of this is 
difficult to assess. 
Tn summary, a number of neuropeptides were shown to effect LHRH 
and IR...'> release from incubated hypothalami. These data support 
the concept of a neuromodulator or neurotransmitter role for 
neuropeptides in regulating hypothalamic and other CNS neuropeptide 
hormone secretion. In particular some known systemic effects 
such as the stimulatory effect of substance P and neurotensin on 
GR, TSH, FSP, and LR release may be mediated via influences on 
LHRH and IRS release from the hypothalamus. 
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8. APPLICATION OF THE INCUBATED HYPOTHALAMIC SYSTEM TO STUDY 
THE HYPOTHALAMIC-PITUITARY-GONADAL-AXIS. 
- JUO -
J.NTRODUCTION 
The feedback actions of androgens on LH and FSH secretion are 
potentially mediated directly via feedback at the ~ituitary 
level or indirectly via altering release of hypothalamic releasing 
factors. Androgens can act directly on the ?nterior pituit.ary 
lobe both in vitro (Kao and Weisz, 1975~ Drouin and ·Labri~J976) 
and in vivo (Kingsley and Bogdanove) 1973). However, the relative 
contribution of feedback regulation at the pitui~ary and at the 
hypothalamic level is unknown. Investigations of this nature 
have been hampered by the inability to satisfactorily measure LHRH 
in vivo. Nansel et al (1979) have demonstrated that direct 
androgen feedback on the pituitary is rapid and sensitive enough 
to play a part 1n the physiological regulation of LR release. 
However, it is unlikely that this ~ ffect functions independently 
of an indirect (brain mediated) feedback mechanism. 
Little conclusive evidence exists concerning the effects of 
gonadal hormones on LHRH release from the hypothalamus. Castration 
of male rats decreases hypothalarnii:. LHRH content. Treatment of 
castrated rats with testosterone prevents this decrease in hypothalamic 
LHRH content (Shin et al: 1974, 1976; Cher et al, 1977). These 
ci1anges in hypothalamic LHRH content may reflect alterations of 
either LHRH synthesis or secretion or both. 
In addition to gonadal hormone feedback at the pituitary and/or 
hypothalamic level, short-loop feedback systems may also operate, 
Gonadotrophic hormones may influence LHRH release and LHRH 
may even regulate its own secretion by autoregulation. This 
studies were undertaken to investigate the effects of the steroid 
hormones~ testoster?ne and ~-oestradiol, on LHRH release from 
~ 
the hypothalamus isolated from intact rats (with normal endogenous 
steroid levels) and castrated rats (decreased endogenous steroid 
levels). Short loop feedback regulation on the hypothalamus was 
studied by monitoring the effect of in vitro addition of the 
pituitary hormones LH, FSH and PRL (prolactin) and an LHRH 
analogue,des-GlylO~D-Leu6 ethylamide LHRH>on LHRH release from 
the hypothalamus isolated from intact rats. In all experiments 
IRS release was also measured. 
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8. 1. METHOD 
Male Long Evans rats, 200-250g were used for all experiments.
 
Animals were castrated under ether anaesthesia and were left
 
for two days before treatment was conunenced. This was to 
ensure clearance of all endogenous testicular steroid hormon
es. 
The animals were then injected subcutaneously,daily_, for 7 days 
with 100 µ1 linseed oil either alone or containing 100 Jlg 
testosterone proprionate or 1 pg p-oestradial. Twenty four 
hours after the final injection rats were decapitated and the 
basal LHRH and IRS release from the isolated hypothalamus wa
s 
monitored as described in the Chapter 2. 
The effect of in vitro addition of testosterone (20-50 ng/mli 
p-oestradiol (20-50 pg/ml), ovine LR (J-JOO ng/mll, FSH (500 ng/mll 
10 6 
and des-Gly -D-leu ethylamide LHRH (10-50 ng/mll on hypothalamic 
LHRH and IRS release was examined. Hypothalami were dissecte
d 
as previously described and then preincubated in 1 ml Hank's
 
medium for 45 min. Thereafter, they were incubated for 60 min
 
in 0.5 ml Hank's medium. All test substances were added at t
he 
beginning of the 60 min incubation period. At the end of the
 
incubation period the release of LHRH and IRS into the medium
 
was assayed and uptake and incorporation into protein of [
3H]-
amino acids by hypothalamic tissue was monitored (See Chapter 2). 
1 JO 
6 1 'd d.d ' Des-G y -D-leu ethy ami e LHRH 1 not cross react with LH
RH 
antiserum 1076 (0%) and therefore at the concentration used did 
not interfere in the radioirranunoassay and allowed specific 
determination of released LHRH . 
• 
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8. 2 . RESUL'J'S 
Hypothalami taken from male rats castrated 9 days earlier 
released significantly less LHRH into the incubation medium 
than did hypothalami from control intact rats (Fig. 8.1 ). 
Hypothalami of castrated rats given either 100 µg testosterone 
proprionate or l tig p-oestradiol daily for 7 days,released 
amounts of LHRH into the medium similar to that from hypothalami 
of castrates and significantly less than hypothalami of intact 
rats (Fig. 8.1). 
Hypothalami of intact rats g;i.ven J pg p-oestradiol daily for 
7 days) rel~ased significantly more LHRH into the medium (p < 0. Ol) 
than hypothalami of the intact control rats (Fi& 8.1 ) • 
. 
IRS release from hypothalami cf castrated rats given 1 µg 
}3-oestradiol daily for 7 days, was significantly more than 
released from rat hypothalami isolated from any of the other 
experimental groups (Fig. 8.1 ). Hypothalami taken from castrated 
rats or castrated rats given 100 mg testosterone proprionate 
daily for 7 days, released similar amounts of IRS to that 
,. 
released from hypothalami of the intact control rats (Fig 8.1 ). 
LHRH release from the incubated hypothalamus isolated from 
intact male rats was not altered by the in vitro addition of 
testosterone proprionate, ~-oestradiol, LH, FSH, or LHRH 
analogue (Fig 8.2 ). IRS release was;however, markedly enhanced 
by the i~ vitro addition of p-oestradiol while testosterone 
proprionate, LH, FSH, and LHRH were without effect. 
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8.3. DISCUSSI ON 
I t is well established that LHRH stimul a tes LR and FSH release 
while testosterone inhibits secre tion of the two gonadotrophic 
horn;ones (Labrie et al, 1979). The decrease in LHRH release 
from incubated hypothalami of castrated rats was not overcome 
by treatment of castrates with testosterone or ~-oestradiol. 
Tre atment with I3-oestradiol increased IRS release indicating 
that the steroid penetrated the hypothalamus. The decrease in 
basal LHRH release from the incubated hypothalamus of castrated 
rats is in agreement with Rudenstein et al (1979). More recently 
Dyer et a l (1980) have reported that castration reduced the 
amount of LHRH released from the incubated hypothalamus in response 
to electri cal stimulation. In addition they confirmed the earlier 
findings that there was also a decrease in hypothalamic LHRH content. 
(Shin & Howitt, 1979; Chen et al, 1977; Kalra et al, 1977; 
Rudenstein et al, 1979). These data may appear paradoxical since 
after castration the negative feedback effect of gonadal hormones 
on the hypothalamic - hypophyseal system is abolished and peripheral 
gonadotrophic hormone levels are usually elevated. It is anticipated 
that hypothalamic LHR.q release, particularly the stimulated release, 
would be facilitated in cast rated rats. Clearly, our findings do not 
concur with the classical view of feedback regulation. It is also 
possible that the post castration rise in s{temic LR and possibly 
FSH levels,may deplete the amount of LHRH available for release. 
However, a similar decrease in LHRH content of and release from 
incubated hypothal ami was reported for hypophysectomised rats 
(Rudenstein et al, 1979). This effect was prevented by administration 
of testosterone to the hypophysectomised animals. These results 
sugges t that the e f fects of castration on hypothalamic LHRH release 
are not mediated via the increase in gonadotrophic hormone levels. 
An enhanced pituitar y responsiveness to LHRH within 4 hours of 
castration has recently been reported (Nansel et al, 1979). However, 
the indirect hypothalamic response to steroid withdrawal does not 
occur until 6-8 hours post castration. It is concluded that the 
slower hypothalamic response is the rate limiting component of 
- I il./ -
the overall br~in-pituitary reponse to andro gen withdrawal. 
In the present study lf8 hours were aU.owed for clearance of 
endogenous gonadal steroid hormone . The decrease in the 
circulating l evels of these hormones following castration and 
prior to commencement of steroid treatment could have altered 
the normal hypothalamic LHRH activity . This concept is supported 
by the observed decrease in the electrically stimulated rele ase 
of LHRH from the hypotha lamus of testosterone treated, castrated 
rats (Dyer et al, 1980). In these experiments, three weeks were 
allowed for the clearance of endogenous gonadal hormones prior 
to treatment of rats with 1.25 mg testosterone proprionate for 
three days. This treatment is sufficient to inhibit secretion of 
gonadotrophic hormone s from the pituitary. In contract, Rudenstein 
et al (1979) commenced steroid treatment of castrated rats 
immediately after castration. Furthermore, in hypophysectomised 
animals, unless testosterone treatment commenced immediately, 
there was a decrease in the amount of LHRH released from the 
incubated hypothalami of these animals. In view of these findings 
the time allowed for clearance of endogenous gonadal hormones 
clearly effects the response of the hypothalamus to subsequent 
treatment with steroids. 
In the hypothalamus testosterone can be metabolized to 
dihydrotestosterone (Lieberburg and Mc Ewan, 1977) : and to 
p-oestradial (Selmanoff et al, 1977) which suggests that the 
stimulatory effect of testosterone on LHRH release may require the 
conversion of testosterone to dihydrotestosterone or p-oestradiol. 
The demonstration that p-oestradiol did not enhance LHRH release 
from hypothalami isolated from castrated rats suggests that the 
failure of testosterone to increase LHRH release did not result 
from a failure of tissue to aromatize testosterone to ~-oestradiol. 
In intact rats }3-·0--estradiol significantly increased LHRH release 
over basal secretion. · It is possible that testosterone alone was 
insufficient for normalisation of LHRH release, and other gonadal 
hormones., such as inhibin, maybe involved. Another possibility is 
that castration reduces the number of brain receptors for the 
gonadal hormones. 
• c 
r' 
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In view of the findings presented earlier in this thesis viz. 
t hat the K+-stimulated re l ease of LHRH is c}+ dependent and 
2+ 
the basal release decreased in the absence of extracellular Ca 
(see chapter 4), it may be concluded that there is some measure 
of physiological control over the release of the neuropeptide 
in vitro. Thus it is most unlikely that the basal LHRH release 
observed in the present experiments merely reflects leakage 
from the hypothalamus. Clearly a more detailed study on the 
+ 
effects of castration on the K -stimulated release of LHRH 
from the incubated hypothalamus would be of value • 
Certain neurons projecting to portal capillaries in the 
median eminence are directly or indirectly sensitive to changes 
in the level of gonap.al steroids (Stoeckart et al, 1975). 
Moreover, gonadal steroid treatment exerts a profound change in 
central catecholamine activity, most noteably an increased turnover 
of dopamine (Kizer et al, 1978) and noradrenalin ( Simpkins et al, 1979) 
1980) in MBH neurons. This suggests that catecholamines play a 
role in the regulation of MBH LHRH activity. Thus., although MBH 
may be the focal site of testosterone action (Kalra and Kalra, 1978) 
the direct effect of testosterone on the LHRH neuron may be 
mediated by an intermediary neurotransmitter or neuromodulator. 
Hypothalami of castrated rats treated with p-oestradiol released 
significantly more IRS into the incubation medium than hypothalami 
of castrated rats, or of intact rats treated with p-oestradiol 
or testosterone. This suggests that the stimulatory effect of 
~-oestradiol on IRS is prevented by the presence of testosterone 
and/or other gonadal hormones. Whether this is due to a direct 
effect such as the decrease in endogenous testosterone or an indirect 
effect is unknown. Somatostatin and oestrogen-containing neurons 
are present in close proximity in the paraventricular and arcuate 
nuclei of the rat hypothalamus (Stumpf and Sar, 1977). In the intact 
rat the androgens may exert an inhibitory effect on soIT)atostatin 
neurons while the positive effect of oestrogen is only shown 
when androgens are removed. 
- · 
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It seems llllikely that the effect of ~-oestradiol is due to the 
somatostatin neurons being more superficially situated in the 
hypothalamus as they show similar distribution of LHRH-containing 
neurons (Stumpf and Sar, 1977; Terry and Martin, 1978). Thus 
potentially there is equal opportunity for interaction with both 
sets of neurons. In view of a similar effect of ~-oestradiol on 
IRS release in the in vitro and in vivo experiments it is likely 
that there is a direct effect of p-oestradiol on IRS release 
from the hypothalamus which does not require chronic exposure 
to the oestrogen. 
-117-· 
9. CONCLUDING DISCUSSION 
• 
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Considerable indirec t information on the secretion of LB.RH and 
somatostatin has accumulated by measurement of the pituitary 
hormones which they regulate. However, there is considerably 
less known about the direct r e lease of these neuropeptides from 
the hypothalamus. The incubated hypothalamus, hypothalamic 
frag. ~ents/_s lices, hypothalamic organ culture, hypothalamic 
synaptosomes and perifused hypothalami are all invitro systems 
which have -been us ed to study f actors influencing neuropeptide 
release from the hypothalamus ( Rotsztejn, et al 1976 , 1977, 1978; Negro-Vilar 
et a l, 1978 , 1979; Ojeda et al, 1979; Hirooka et al, 1978·; Hollander 
et al~ 1980; Bennett et al., 1975, 1979; Wakabayashi et al1 1977, 
Berelowi tz et al, 1978, 1980; Sheppard et al_, 1979, 1980; Maeda and 
Frohman 1980; Richardson et al,1980·; Hart:"ter and Ramirez,1980) . 
However conditions for maintaining the viability of the tissue have 
not been clearly established. In the results presented in this thesis 
it has been shown that monitoring protein synthesis in the incubated 
hypothalamus is a clear and reliable index of hypothalamic functional 
viabil ity. 
Stirnulus-~ecretion-coupling involves· depolarisation of the plasma 
membrane and leads to an increased membrane ion permeability. This 
. . fl f 2+ . h 1 f h 11 1 permits in ux o Ca into t e cytop asm . rom t e extrace u ar 
fluid through voltage-dependent channels in :the plasma membrane. 
This ca2+ influx initiates· the cascade of events culminating in the 
releas e of neuropeptide from the celL (Douglas 1975, Thorn et a~ 1978). 
LHRH and IR$ release from isolated hypothalami into the incubation 
medium w2s stimula ted by membrane-depolarising concentrations of 
potassium and ov:abain . This release was ca~+- dependent and was 
inhibited when Ca
2
+ was omitted from the incubation medium. However 
2+ . + 
there are clearly differences in the Ca requirements for the K -
stimulated release of LHRH and IRS. Verapamil completely blocked 
+ K.·-stimulated LHRH release but only partially blocked the release 
of IRS. Moreover, this suggestion of differences in the mechanism 
of release of the two neuropeptides was emphasised by the different 
effects of the ionophores. X537A stimulated both LHRH 
and IRS release, only the LHRH release was inhibited by verapamil. 
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Similarly i0nophore A23187 stimulated IRS release alone. This 
release was calcium- dependent but was not blocked by verapamil. 
Although these results again sugge st a difference in release 
mechanisms for the two neuropeptides the results cannot necessarily 
be interpreted as indicating differences in ca
2
+ requirements 
since the iouophores have diverse effects on membrane properties 
(Cochrane and Douglas, 1975; Klausner et al, 1979; Brmvn et al, 1980).. 
Although release of LHRH and IRS into the incubation medium cannot 
be equated with secretion in vivo it was demonstrated that 
LHRH and IRS release can be induced by membrane depolarisation 
2+ (60 mM KCl) and Ca influx. This suggests that the release of I 
the neuropeptides in the system described is under the control of 
at least some of the satoe physiological factors that influence 
the secretion of most hormones in vivo .' 
In recent years it has become clear that neurotransmitters and 
neuropeptides can act in many different brain regions, sometimes 
even evoking opposite responses at different sites, to regulate 
hormone release from the pituitary or the hypothalamus (Moss, ]979; 
Krulich, 1979). The putative role of neuropeptides as central 
neurotransmitters or neuromodulators implies that they can effect 
the release of other neuropeptides. Thus, in the present experiments; 
it is suggested that oxytocin and vasopressin have a modulatory role 
in regulating the release of LHRH. Similarly,neurotensin and substance p 
increased IRS release. The regulation of IRS release at the hypothalamic 
level by these neuropeptides explains,in part, the observed decrease 
in serum GR and TSH levels following intraventricular injection of 
neurotensin or substance P (Rivier et al, 1977; Chihara et al, 1978).. 
A similar modulatory influence on LHRH and IRS release was observed 
with neurotransmitters . 
• 
The release of LHRH and IRS from the hypothalamus can be 
modified by many different factors such as the age, sex, endocrine 
status of the animal and steroid priming. However, the final 
effect of a neuropeptide or neurotransmitter on LHRH and IRS 
release may depend on the differential effect of a second neuromodulator 
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at a different site of act ion . In view of the demons trat i on of 
axo-axoni c and dendro-dendrit i c contacts of hypotha l amic pep t i de
rgic 
neurons wi th catecholamine contai n ing neurons (Ajika, 1979) we 
have concurrently inves t igated peptide release fr om the i nc ubated
 
hypothal amus and from hypo thalamic synaptosomes. Thus we were 
ab le t o different i a te event s involvi ng the entire neuron from 
tho se occurring a t the nerve t ermina l. 
A dir ect androgen f eedback mechanism on the regulation of LH 
release has r ecently been demonstrated (Nans e l et al, 1979). 
It appears t hat t his mechanism cannot operate independently of an
 
ind i r ect (bra i n-mediated) f eedback mechanism. The criterion 'of an 
indirec t feedback mechan ism is evidence that feedback signals 
produce appr opriate alteration in the hypophys iotropin r e l ease 
(Nan sel et al, 1979). Cas tration and/or androgen treatment have only 
recently been shown to alter LHRH release from the incub a t ed 
hypo t halamus· in vitro (Rudenstein et al, 1979)_ and to decrease 
hypotha lamic LRRH content (Shin and Howitt, 1974, )976; Chen et 
al, 1977; Ka lra et al, 1977; Rudenstein et al, 1979; Dyer et al, 198
0). 
"~ile p-oestradiol and t e stosterone did not effect LHRR s ecretion
 
when added to the incubation medium i:E. vitro, the . in vivo modulation 
of steroid hormones did effect LHRR release from the hypothalamus
· 
isolated from trea ted animals. Castration induced a significant 
decrease in LHRH r e lease which was not overcome when treatment w
ith 
te s tosterone proprionate or ~-oestiodiol, connnenced 2 days post 
castration. The increase in serum LR levels following castration
 has 
been ascribed to increased sensitivity of the pituitary to less t
han 
normal concentrations of LRRR (Nansel et al, 1979) .• Administration of 
LHRH to castrates, enhanced this LR secretion while the administr
ation 
of testosterone to castrates decreased the LR response to LHRH. 
Our re sults suggest that the fall in endogenous gonadal hormones 
in the two days _J)ost castration, and prior to treatment, alters 
the hypophysiotropi~ activity. This effect cannot be overcome by 
the subsequent treatment with testosterone or ~-oestradiol. These
 
.f--data suggest a direct action of thP gonadal hormones on hypotha
lamic 
hypophysiotropi c releasing activity which is in agree~ent with N
ansel 
I 
- ' • 
et -al (1979). These data also support the hypothesis that gonadal steroids 
may Maintain LHRH secretion in vivo.In addition these findings su
ggest 
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that LHRH release is not affected by acute administration of 
testosterone anq ~-oestradiol and that feedback regulation 
is associated with chronic exposure to the hormones. 
Thus the present thesis has demonstrated the use of the incubated 
hypothalamus for studying the in vitro release of LHRH and IRS. 
It has described both similarities and differences in the release 
of LHRH and IRS and shown that the mechanism of release of the 
two neuropeptides is clearly different. Used in conjunction with in 
vivo experiments the isolated hypothalamus provides a valuable 
tool for unfolding the nature of physiological control of endocrine 
function and in particular feedback inhibition. Thus the hypothalamus 
provides a useful approach to the elucidation of the mechanisms 
of hormonal homeostasis. 
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